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Trypanosoma brucei, a causative agent of African sleeping sickness in humans
and nagana in animals, constantly changes its dense variant surface glycoprotein (VSG)
coat to avoid elimination by the immune system of its mammalian host, using an
extensive repertoire of dedicated genes. Although this process, referred to as antigenic
variation, is the major mechanism of pathogenesis for T. brucei, the dynamics of VSG
expression in T. brucei during an infection are poorly understood.
In this thesis, I describe the development of VSG-seq, a method for quantitatively
examining the diversity of expressed VSGs in any population of trypanosomes. Using
VSG-seq, I monitored VSG expression dynamics in vivo during both acute and chronic
mouse infections. My experiments revealed unexpected diversity within parasite
populations, and the expression of as much as one-third of the functional genomic VSG
repertoire after only one month of infection.
In addition to suggesting that the host-pathogen interaction in T. brucei infection
is substantially more dynamic and nuanced than previously expected, this observed
diversity highlighted the importance of the mechanisms by which T. brucei diversifies its
genome-encoded VSG repertoire. During infection, the parasite can form mosaic VSGs,
novel variants that arise through recombination events within the parasite genome during
infection. Though these novel variants had been identified previously, little was known

about the mechanisms by which they form. VSG-seq facilitated the identification of
mosaic VSGs during the infection, which allowed me to track their formation over time.
My results provide the first temporal data on the formation of these variants and suggest
that mosaic VSGs likely form at sites of VSG transcription.
VSG-seq, which is based on the de novo assembly of VSGs, obviates the
requirement for a reference genome for the analysis of expressed VSG populations. This
allows the method to be used for the high-resolution study of VSG expression in any
strain of T. brucei, whether in the lab or in the field. To this end, I have applied VSG-seq
to samples grown in vitro, parasites isolated from natural infections, and extravascular
parasites occupying various tissues in vivo. These extensions of the method reveal new
aspects of T. brucei biology and demonstrate the potential of high-throughput approaches
for studying antigenic variation, both in trypanosomes and in any pathogen that uses
antigenic variation as a means of immune evasion.
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CHAPTER 1. Introduction

1.1 Trypanosoma brucei
African sleeping sickness, or human African trypanosomiasis (HAT), is a vectorborne disease affecting sub-Saharan Africa. It is fatal if left untreated, most existing
drugs are extremely toxic, and the economic burden of sleeping sickness, along with its
zoonotic counterpart, nagana, is estimated to be at least 1.5 billion USD per year1. The
economic burden of this disease is due largely to the animal infection, which commonly
affects livestock and can be devastating to endemic areas. In fact, there are probably only
approximately 20,000 cases of HAT per year2. However, underreporting is a problem in
the poor rural areas typically affected by HAT, so estimating its prevalence can be
difficult. Nevertheless, the diseases caused by African trypanosomes represent a major
barrier to economic development in affected regions.
The causative agents of sleeping sickness and nagana are a group of protozoan
parasites known as the African trypanosomes, of which there are two human-infective
subspecies: Trypanosoma brucei gambiense, which is found in west and central Africa
and causes a chronic infection lasting months to years, and T. brucei rhodesiense, which
is found in east Africa and causes an acute form of the disease lasting weeks to months.
Humans are resistant to T. brucei brucei as well as a number of other species of
Trypanosoma, meaning that only animals are infected by these parasites. T. brucei is
limited geographically to the range of its vector, the tsetse (Glossina sp.), but two African
trypanosome species, T. evansi and T. equiperdum, which are actually probably
subspecies of T. brucei3, have evolved new modes of transmission, expanding their range
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beyond sub-Saharan Africa into Asia and South America. Thus, the range of the African
trypanosomes and the diseases they cause is large and has the potential to expand. Of all
of the African trypanosomes, however, T. brucei is the most commonly studied in the
laboratory and will be the focus of this thesis.
T. brucei’s entirely extracellular life cycle (Figure 1.1) begins when its vector, the
tsetse, takes a blood meal from a mammal, transferring metacyclic stage parasites to a
new mammalian host. These metacyclic forms move from the skin to the bloodstream
where they transform into long slender bloodstream form parasites. The long slender
forms divide quickly. As their density increases, they undergo quorum sensing and some
of the long slender population transforms into non-dividing short stumpy bloodstream
form parasites, which are primed for transmission back to the fly4,5.
When a fly bites an infected mammal, these short stumpy trypanosomes are taken
up and move to the midgut of the fly, where they transform into procyclic form parasites.
The procyclic forms then move to the fly’s salivary glands, where they further develop
into epimastigote form parasites which can undergo meiosis, allowing for genetic
exchange between parasites6,7. The epimastigotes divide for some time in the salivary
gland before finally becoming metacyclics once again. These parasites can then be
transmitted to a new host at the fly’s next blood meal.
During a mammalian infection, long slender and short stumpy trypanosomes
reside both in the blood and in tissues8 but appear to always live extracellularly. In the
early stages of infection, patients experience non-specific symptoms such as fever and
headaches. Eventually, parasites cross the blood-brain barrier and enter the central
nervous system, though the timing of this transit can vary9,10. This infection of the brain
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and cerebrospinal fluid defines late-stage infection, and results in severe neuropathology,
including the disturbance of the circadian rhythm that gives sleeping sickness its name11.
The drugs required to treat this stage of infection are difficult to administer and
frequently toxic12. Although prevention of African trypanosomiasis would be ideal, there
is little hope for a vaccine against T. brucei13,14. One major reason why a vaccine proves
unlikely is T. brucei’s capacity for antigenic variation, the parasite’s primary mechanism
of immune evasion.

Long Slender
Bloodstream Form

Mammalian Host

Short Stumpy
Bloodstream Form

Metacyclic

Insect Vector
(Glossina)

Epimastigote
(Salivary Gland)

Procyclic
(Midgut)

Figure 1.1. The life cycle of T. brucei.
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1.2 The variant surface glycoprotein and antigenic variation
In 1909, Ross and Thomson applied a new method for counting parasites to the
blood samples of a patient infected with T. b. gambiense. Their methodical counting
revealed the periodic peaks and valleys in parasitemia characteristic of T. brucei
infections15(Figure 1.2), and they and others hypothesized that these waves resulted from
some kind of habituation to host antibody16. Their guess was not too far off. Decades
later, the antigenic component of T. brucei responsible for the waves of parasitemia
during infection was identified as variant surface glycoprotein (VSG)17, and these waves,
we now understand, are the result of a sort of habituation: T. brucei periodically
“switches” an antigenic VSG coat, allowing the parasite to escape recognition by host

Parasites/ml of blood

antibody.

Weeks from probable time of infection

Figure 1.2. Waves of parasitemia during infection.
Image adapted from Ross and Thomson, 1910.
VSG, a GPI-anchored glycoprotein, is extremely densely packed on the cell
surface of metacyclic and bloodstream form parasites18, comprising ~95% of the surface
proteome19 with approximately 107 identical copies of the protein covering the
parasite17,20. Due to its abundance, VSG is effectively the only protein “seen” by the host
immune system. Though the host may mount a response to other trypanosome proteins,
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no other protein can elicit a significant or protective immune response21,22. Therefore,
changing the VSG coat renders a parasite temporarily invisible to the host, prolonging
infection.
Each VSG is composed of a relatively conserved membrane-proximal C-terminal
domain and a more variable N-terminal domain (Figure 1.3). Only two VSG crystal
structures exist, and these structures only contain VSG N-termini23,24. Interestingly, the
structures are superimposable despite only 16% sequence identity24. Analysis of the
sequence of VSG-encoding genes has identified conserved cysteine residues that may
play a role in maintaining VSG structure while allowing for such significant sequence
divergence25.

N-terminus

C-terminus

Figure 1.3. The VSG coat.
The Variant Surface Glycoprotein (VSG) densely coats the parasite membrane, as shown
by electron micrograph (courtesy of George A.M. Cross) displayed in. 10 million VSG
molecules pack on the surface of the parasite cell (image courtesy of Markus Engstler).
The parasite takes advantage of its set of structurally similar but antigenically
diverse VSGs during antigenic variation, the mechanism by which T. brucei changes its
VSG coat to avoid recognition by the host immune system. Throughout infection, the
parasite turns on and off expression of individual VSG-encoding genes, from a genomic
repertoire of ~2000 different genes26,27. As the host immune system recognizes and clears
a VSG expressed within a population of parasites, a minority of parasites will have
5

	
  
already changed their VSG coat, turning on a new, and likely antigenically distinct, VSG.
These “switchers” will eventually be recognized by the immune system, but not before
another set of parasites has turned on another VSG and escaped immune clearance.
The process of antigenic variation is common to many pathogens, including
viruses28, bacteria29, and other protozoa30 such as the malaria parasite Plasmodium
falciparum31. T. brucei, then, can be thought of as a tractable model for an important
process common to many organisms relevant to public health.

1.3 VSG expression
In bloodstream form parasites, VSGs are expressed from one of ~15 telomeric
bloodstream expression sites (BESs)32(Figure 1.4A). Only one BES is ever transcribed at
a time, though the mechanisms controlling this monoallelic expression are not well
understood. Each BES is made up of a promoter, a collection of expression site
associated genes (ESAGs), a 70-bp repeat sequence, and a VSG. The number and identity
of ESAGs can vary among sites, and it is not clear whether these genes play a role in
antigenic variation; many are also expressed from other loci within the genome and
during other life cycle stages33,34. The 70-bp repeat adjacent to the VSG can vary in length
between BESs, and the sequence is speculated to play a role in antigenic variation by
allowing VSG switching to diverse genomic donor sequences35-38.
The entire BES, from just downstream of the promoter39 through the VSG, is
polycistronically transcribed by RNA Polymerase I (Pol I)40. This polymerase is
exclusively responsible for transcription of ribosomal RNA in other organisms, and its
role in VSG expression may be due to the high level of expression required to produce
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sufficient VSG to cover T. brucei’s surface. This long Pol I-transcribed unit is then
processed into individual transcripts and, as is the case for all T. brucei mRNAs, a 5ʹ
spliced-leader sequence is trans-spliced onto each gene, including the VSG41(Figure
1.4B). Though VSG sequences are quite divergent from one another at the DNA level,
they all contain a conserved 14 base pair (bp) sequence in their 3ʹ untranslated region
(UTR)42. This sequence may play a role in maintaining monoallelic expression of VSG,
although its precise role in the process is not well understood.

A
P

VSG

70 bp

ESAGs

B 5’
Spliced Leader
Sequence

3’

VSG

14mer
(3’ UTR)

Poly(A)

VSG mRNA

Figure 1.4. VSG expression.
(A) Schematic of a BES. (B) Schematic of a mature VSG mRNA.

Though not the focus of this thesis, metacyclic VSGs are expressed from a
specialized expression site in metacyclic form parasites43,44. This site is also telomeric,
but it lacks ESAGS and the 70-bp repeat sequence. Metacyclic expression sites have a
promoter sequence distinct from that of bloodstream forms26,45,46.
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1.4 VSG switching
There are two broad mechanisms by which T. brucei switches VSG expression.
The first mechanism is transcriptional, or in situ, switching, during which transcription at
one BES is turned off and transcription at a second BES is turned on47 (Figure 1.5A). It is
not clear how an in situ switch is initiated. The second mechanism is recombinationbased switching. This can occurs in two ways: duplicative gene conversion (GC) and
telomere exchange (TE). Telomere exchange occurs through a homologous
recombination event in which telomere ends are swapped between two chromosomes,
resulting in a new VSG in the active BES, but retaining the previously active
VSG48(Figure 1.5B). GC, on the other hand, occurs though a homologous recombination
event in which a VSG located in a distant site is copied into the active BES. This results
in the loss of the previously expressed VSG and duplication of the donor VSG sequence
(Figure 1.5C). This type of switch can be initiated by a DNA double-strand break
(DSB)49,50 within the active BES, which is then repaired by gene conversion. A number
of genes known to be involved in homologous recombination in eukaryotes have been
implicated in this process51,52. While it is thought that recombinatorial switching results
from naturally occurring DSBs, and that subtelomeric fragility may play a role in the
induction of breaks in a BES50,53,54, it is not clear whether this process is wholly
stochastic.
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VSG C

P

VSG B

P

VSG C

P

Gene conversion

P
P
P

VSG A

VSG C

P
VSG B

VSG B

P
VSG C

Monoallelic expression

Recombinatorial
switching

VSG A

P

Telomere exchange

VSG A

P

VSG B

P

Transcriptional
switching

VSG C

P

in situ switch

Figure 1.5. Mechanisms of VSG switching.
T. brucei can switch expression to an antigenically distinct VSG by recombinatorial (top,
GC and TE) or transcriptional (bottom) switching.

1.5 The genomic VSG repertoire
GC based switching, in particular, is extremely important because it allows access
to the extensive genomic repertoire of VSGs. The key to antigenic variation is the extent
of this repertoire: recent work sequencing the “VSGnome” of the T. brucei Lister 427
strain revealed more than 2000 different VSG-encoding genes26. The telomeric BESs
contain one set of VSGs, but these only represent a small fraction of the repertoire. The
majority of VSG genes and pseudogenes exist elsewhere in the genome (Figure 1.6). The
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rest of the VSG archive can be found within intra-chromosomal arrays27,55 or in the
minichromosomes (MCs). MCs are small 30-150kb chromosomes consisting only of VSG
sequences, a 177-bp repeat sequence, and telomeres56. The enrichment for VSG within
MCs suggest these tiny chromosomes play a role in antigenic variation, but this role has
not yet been elucidated. Interesting, the majority of MC VSGs are complete VSGs that
should produce a full-length and functional VSG26. This is in contrast to the rest of the
VSG archive, which is primarily composed of incomplete VSGs or VSG pseudogenes. In
fact, studies of two strains of T. brucei, the Lister 427 strain and the TREU927 genome
strain, show >80% of genomic VSG sequences are incomplete or pseudogenous26,57.
~15 expression-site (ES) associated VSGs
VSG

P

70 bp

ESAGs

~100 minichromosomal VSGs
VSG

70
bp

70
bp

VSG VSG

177bp

~1000 chromosome-internal VSGs
VSG
Pseudogenes or ESAGs

70
bp

Figure 1.6. The genomic VSG archive.
The extensive repertoire of VSG genes is located in various sites throughout the genome.
Around 15 VSGs are associated with expression sites, where they are transcribed with a
cohort of Expression Site Associated Genes (ESAGs). Expression sites also contain
repetitive 70bp repeat elements. Around 100 VSGs are located on ~100
minichromosomes. Finally, a large number of VSGs are located in chromosome-internal
regions, where they are often found in combination with ESAGs and repetitive elements.
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1.7 Mosaic VSGs
The presence of so many pseudogenes might at first suggest a very limited
repertoire of VSG genes from which the parasite can draw during an infection. Although
there are ~2000 VSG sequences in the genome, only ~400 are obviously capable of being
used. What purpose could a repertoire of partial VSG genes serve? It appears that this
repertoire of partial VSGs and VSG pseudogenes may actually be extremely important to
T. brucei infection. Various studies have identified expressed VSGs that appear to have
undergone incomplete gene conversion events, in which part of a VSG recombines with
another VSG, resulting in new, chimeric, variants58-63. This chimeric VSG sequence is
referred to as a “mosaic VSG” (Figure 1.7). Such mosaic variants are usually detected in
vivo after the first few waves of parasitemia (~3 weeks of infection in a mouse)64.
Reports of mosaic VSGs appearing only after the initial peaks of infection suggest
that not only is the genomic repertoire of VSGs extended by the formation of mosaics, but
that this extension of the repertoire may be required to sustain a chronic infection. That
is, the repertoire of functional VSG genes is insufficient for escape from the host immune
system over the course the months- or years-long infections observed in the wild65.
Notably, the use of recombination for generating antigenic diversity within the genome is
common to a number of pathogens that undergo antigenic variation, including Borellia
burgdorferi66, Anaplasma marginale67, and P. falciparum68, so this may be a common
strategy for immune evasion. Some studies have suggested an even greater extension of
the VSG repertoire through the introduction of point mutations during gene conversion
events69,70, although others argue that this is not a significant source of VSG diversity71.
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VSG pseudogenes

Expressed
Mosaic VSG

(lines indicate stop codons)

Figure 1.7. Mosaic VSG can form by recombination between pseudogenes.

1.7 Mechanisms of mosaic formation
Although many instances of mosaic VSGs have been described, very little is
known about when or where these variants form. It has been hypothesized that gene
conversion in general and VSG switching in particular are facilitated by microhomologymediated end-joining in T. brucei72,73. Thus, this mechanism is expected to be involved in
the formation of mosaic VSGs as well. A recent study attempted to tackle the formation
of mosaic VSGs in vivo in depth by cloning and sequencing hundreds of expressed VSGs
over the course of mouse infections64. In this extensive analysis, mosaic VSG donor
sequences did indeed typically show homology with one another. It did not appear,
however, that homology at the site of gene conversion was required for the formation of
mosaic VSG genes; there were mosaic VSGs in which the boundaries of segmental gene
conversion between donors showed absolutely no homology64. However, it is important
to note that determining the precise source of donor sequence for each mosaic can be
complicated, as the genomic VSG archive is complex and only partly known in this
study64. Frequently VSG sequences share significant stretches of homology26,57 that can
complicate analysis.
Whether DSBs initiate the formation of mosaic VSGs, as is the case for GC
switching in general, is not clear. Moreover, because most studies are limited to analysis
of expressed VSGs and not the evolution of the genomic archive, is not clear where in the
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genome mosaic VSGs form. The gene conversion events resulting in mosaic VSGs could
occur within a telomeric BES or throughout the silent VSG archive. Because previous
studies have been somewhat limited in resolution61,62,74-76, it has also been impossible to
determine how frequently mosaic variants form. Although long recognized as an
important aspect of antigenic variation in T. brucei, the mechanisms of mosaic VSG
formation remain largely mysterious.

1.8 Order in VSG switching
Just as mosaic VSGs generally appear late in infection, it has been observed in
many in vivo studies that other VSGs are more likely to arise early in infection47,77-80.
While some work suggests that this can be explained in part by differences in growth rate
(i.e. a variant that grows the fastest will appear first)78,81, this view has been challenged82.
Telomeric VSGs are thought to arise early in infection47, followed by intact but nontelomeric variants27,55. Finally, mosaic VSGs comprised of pseudogenes tend to appear
after the other sets of functional VSGs have been expressed64.
The factors driving this preference are not well understood, but a number of
groups have attempted to explain the predicted order of VSG switching with modeling.
One model suggests that the order observed during infection arises solely from parasiteintrinsic factors, rather than the host milieu81. Intuitively, it makes sense for genomic
location to determine the probability of a switch to a given VSG: a VSG within a BES
only requires that BES be activated, and a complete VSG near a telomere provides
straightforward homology for transposition the active BES. Mosaic variants, on the other
hand, are likely to be subject to frequent failure due to the requirement that a recombinant
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VSG produce an in-frame open reading frame and a properly folding protein. Thus, only
when the repertoire of complete and easily expressed VSGs has been exhausted do these
harder-to-produce variants emerge.
Other models, however, suggest that the activation probabilities of VSGs in
different locations are not the only players in determining VSG order. Some suggest that
genomic location in combination with the effects of immune cross-reactivity to certain
VSGs83,84 determines VSG order during infection, while other models propose that the
host immune system is the chief player in determining VSG order, primarily through
cross-reactive epitopes85,86. A discussion of the specific ways in which the host immune
response could affect VSG order and switching dynamics will follow in sections 1.12
through 1.15.

1.9 Dynamics of antigenic variation
The extensive modeling of VSG switching in vivo highlights the fact that the
dynamics of this process are a lingering question in T. brucei biology. Despite so many
attempts at modeling5,78,81,82,84,85, little is known about the kinetics of VSG expression
during infection. To date, the resolution of most studies of VSG switching in T. brucei in
vivo has been quite low, examining only a handful of variants at any given time, such that
these kinetics could not be measured directly47,79,80,87,88. Moreover, many factors on both
the parasite and host side of this system work together to produce the observed peaks and
valleys of parasitemia during infection, the VSGs arising within those peaks, and the
VSGs cleared from those peaks. Parasite-intrinsic factors include the genomic archive of
VSGs and the molecular mechanisms driving switching discussed previously, as well as
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the rate at which switching occurs in a population. On the host side, the recognition of
parasites by the host immune system and the dynamics and mechanisms of clearance of
each variant will also likely affect the kinetics of observed VSG expression in vivo.

1.10 Antigenic variation in vivo: Rates of switching
A major parasite-intrinsic factor likely to affect VSG expression dynamics during
infection is the rate at which switching occurs in T. brucei. Despite T. brucei’s large
repertoire of VSGs, it is thought that the rate of switching must be tightly controlled. If
switching is too slow, the immune system will recognize the expressed VSG and clear the
infection, preventing transmission to the tsetse. If switching is too fast, it is possible that
the VSG repertoire will be exhausted prematurely. Many measurements of VSG switching
rates have been made, both in vivo and in vitro. In laboratory adapted strains the rates of
switching have been measured to be between 10-5 to 10-7 switches/parasite/population
doubling both in vivo87,89,90 and in vitro89-91. Many interpret the in vitro data to suggest
that the process of switching is purely stochastic, but some studies have shown the rate of
switching in naturally occurring (fly-transmitted) infections to be much higher, perhaps
as high as 1 in 10087,88. These findings suggest that there may be some environmental cue
initiating or influencing VSG switching.
Determining the true rate of VSG switching during infection presents
experimental challenges, however. Trypanosomes expressing different VSGs may grow at
different rates, or trypanosomes may switch to a VSG for which the immune system has
already mounted a full or partial response. As a result, even if a switch occurs, that
switched variant may never establish in the measured population. Additionally, the non-
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dividing short stumpy form of T. brucei appears to be incapable of switching4. The
number of short stumpy parasites present at any time fluctuates throughout infection5,
and thus the number of parasites capable of switching at any given time also fluctuates
throughout infection.

1.11 Antigenic variation in vivo: Diversity
One measure that may indirectly indicate the rate at which switching occurs in
vivo, however, is VSG diversity within parasite populations. If switching occurs
infrequently, populations should be relatively less diverse. Typically, antigenic variation
is depicted by a schematic showing only one or a few variants per parasitemic peak
(Figure 1.8). This model suggests a rate of switching just sufficient for immune evasion
that also most efficiently preserves the VSG repertoire. Experimental data, however,
suggest this is unlikely to be the case. The most comprehensive study of expressed VSG
populations to date estimated, but did not measure directly, as many as ~100 VSGs could
be expressed at any given time during an infection64. Other studies have also detected
multiple VSGs expressed at the same time, though the experiments looked at so few VSGs
that these observations are hard to interpret47,64,79,80,88. A recent study of parasites isolated
from human infections also showed VSG diversity higher than the typical depiction of
antigenic variation would imply92. This suggests that VSG diversity is not an artifact of
the mouse infection model. It is also important to note that T. brucei is extracellular but
not exclusively vascular. Trypanosomes can sequester in extravascular spaces93, and most
studies so far have examined only populations in the bloodstream. This could lead to an
underestimation of diversity and switching frequency in vivo.
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Figure 1.8. VSG diversity in vivo.
The textbook depiction of VSG diversity in vivo (left) shows only a handful of variants at
each peak, but low-throughput experiments predict much higher diversity (right). The
predicted model had not been tested at the time I started my studies.
1.12 The B cell response to T. brucei
The dynamics of antigenic variation during an infection are likely to be affected
by T. brucei’s interaction with its host, which determines the rate and mechanisms by
which parasites are cleared, likely in response to each novel VSG. Given the parasite’s
extracellular lifestyle, it is no surprise that the immune response to T. brucei is largely B
cell mediated. A number of studies, however, highlight the complexity of the B cell
response in the arms race between T. brucei and its host. One study reported non-specific
polyclonal B cell activation in response to T. brucei infection94, although VSG-specific
antibodies can also be detected during infection95,96. In addition, certain B cell
populations have been reported to be lost during T. brucei infection, specifically IgM
marginal zone B cells in the spleen. This loss of marginal zone B cells coincides with a
loss of vaccine-induced protection against Bordetella pertussis in vaccinated mice
challenged during T. brucei infection97. Overall, these studies and others98,99 suggest that
B cell exhaustion may take place during T. brucei infection. This could occur either
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directly through an interaction between the trypanosome and host, or perhaps more likely,
through the constant presentation of new antigens via antigenic variation over the long
course of infection. This, of course, could have an effect on the outcomes of antigenic
variation in vivo. If B cell memory is lost, for example, it is likely that antigenic variants
that occurred earlier in infection will reappear. Additionally, the diversity of VSG
populations might increase over time, in synchrony with a weakening B cell response.
Thus, an understanding of the dynamics of antigenic variation could shed light on the
immune response to VSG, and an understanding of the immune response to VSG could
shed light on the dynamics of antigenic variation.
In terms of antibody isotype, it is generally thought that IgM B cells mediate the
response to T. brucei and VSG. This conclusion is based on a study tracking VSGspecific antibody titers during T. brucei infections96 that showed IgM appearing earliest
in infection and persisting longer than other isotypes. VSG-specific IgG did not appear
until after the first peak of parasitemia was cleared, leading the authors to conclude that
the IgM response was responsible for clearance of each variant. On the other hand, IgM-/mice are still capable of maintaining a chronic infection100. Further complicating matters,
IgM-/- mice express compensatory IgD101, an isotype whose function in the immune
response is an enduring mystery102, as well as VSG-specific IgG2a and IgG3. Yet another
study suggests that the anti-VSG antibody response is different from the response to other
surface proteins103 in terms of isotype. This study did not determine whether this
variability in antibody response could vary among different VSGs. Thus, the importance
of IgM, in comparison to other isotypes, in the VSG-specific immune response remains
an open question.
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1.13 Antibody-parasite interactions
The specific role of IgM in parasite recognition and clearance, though not yet
clear, is critical for understanding how antibody interacts with VSG. Generally, it is
thought that only the most N-terminal regions of the VSG can be recognized by antibody,
due to the density of the VSG coat. The coat, extending ~12-15nM from the cell
membrane104,105 is thought to “shield” invariant surface proteins as well as the relatively
buried C-terminal domain of VSG from binding by host antibody106. This shielding of
epitopes is important for immune evasion, as it prevents recognition of invariant epitopes,
both on invariant surface proteins and in the relatively conserved VSG C-terminal
domain.
The specific role of each antibody isotype in recognizing VSG is important
because it may determine the degree to which these epitopes are shielded. There is
evidence that IgG can reach at least partially into the VSG monolayer107, though the
integrity of the VSG coat is suspect in some experimental situations. Additionally,
epitopes have been described that appear more membrane-proximal than expected, quite
close to the buried end of the VSG, rather than at the exposed and variable N-terminus105.
On the other hand, modeling of the protein structure of a handful of mosaic VSGs
showed that many of the distinct residues on related mosaics occurred in the N-terminal
portion of the VSG, likely to be exposed on the trypanosome surface and thus most
immunogenic64. If the primary isotype recognizing VSG in a natural infection is IgM,
VSG-internal epitopes may not be relevant to parasite clearance. Therefore, the epitopes
recognized by the host are likely to be determined by the antibody isotype dominating the
B cell response to VSG as well as by each specific antibody-VSG interaction.
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Besides potentially shielding internal and invariant epitopes, the VSG coat
functions to selectively degrade VSG-specific antibodies, thus dampening the host
antibody response108. All endocytosis and exocytosis occurs through the flagellar pocket
of the parasite109, and VSG is continuously endocytosed at this location110. The parasite
quickly degrades antibody bound to endocytosed VSG while shuttling the VSG, now
cleared of bound antibody, back to the surface. Though the precise molecular mechanism
that underlies this process is not completely clear, it appears to occur through
hydrodynamic-flow-mediated forces, with the bound antibody acting as a “molecular
sail”. Again, the specific isotypes recognizing VSG affect immune evasion: due to
hydrodynamic flow, antibody-bound VSG reaches the flagellar pocket more quickly than
bare VSG, and the bulky pentameric IgM molecule is cleared more quickly than other
isotypes (e.g. dimeric IgG). Thus the rate of antibody degradation by T. brucei, which can
result in evasion of complement-mediate lysis and opsonization, depends on the specific
host antibodies targeting each VSG.

1.14 Mosaic VSGs and antibody cross-reactivity
The possibility of immune cross-reactivity between VSGs could also have
consequences on the dynamics of antigenic variation in vivo. Mosaic VSGs are
particularly interesting in this respect because they, by definition, share sequence
homology with other VSGs in the genome. This is not exclusive to mosaic VSGs,
however, as many genomic VSGs exist as members of closely related families26 that share
stretches of sequence homology. Thus, the question arises: if similar VSGs are expressed
during the same infection, can pre-existing immunity against a prior variant affect the
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survival of a second variant? Studies of mosaic VSG epitopes suggest this is likely to be
the case. A number of old studies in T. brucei and T. equiperdum, a related species of
trypanosome that infects horses, actually identified mosaic VSGs by their immune crossreactivity61,62,74-76. In these experiments, monoclonal antibodies against a parent VSG
were found to bind epitopes on other VSGs, which were later identified as mosaics. Some
studies have shown, however, that point mutations alone can be sufficient to alter
monoclonal antibody binding69,111. The recent study by Hall et al. identified mosaics with
similar sequence that were nonetheless antigenically distinct, as antibodies raised against
one variant would not cross-react with a related variant from the same infection. Thus, it
is likely that VSG mosaicism can result in a mixture of unique and cross-reactive
epitopes. The relative prevalence of each type of epitope and their relative influence of
VSG dynamics and switching outcomes, however, is unknown.

1.15 The T cell response to T. brucei and T cell recognition of VSG
The T cell response to T. brucei has also been characterized112 and it appears to be
central to eliciting an IFN-γ response during infection, which is a major determinant in
resistance and susceptibility to infection113. Interestingly, although T cells have access to
any VSG peptide, including the much more conserved VSG C-terminal domain, on study
showed that T cells only present peptides from the more variable N-terminal domain 114.
Somehow, the parasite manages to avoid immune recognition at invariant regions of the
VSG. Thus, both arms of the adaptive immune system primarily recognize the variable,
and exposed, N-terminal domain of VSG.
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1.16 Outstanding questions
The interaction between host and VSG, though it has been well studied
throughout the years, is not yet well understood. It is still unclear precisely how VSG is
recognized by antibody or how that results in parasite clearance. It is still unclear how
often switching occurs in vivo. The determinants of order in VSG switching are still
unknown. The mechanisms of mosaic VSG formation remain a mystery.
Overall, antigenic variation in T. brucei in the mammalian host occurs in the
context of an extremely complex system. The first step towards understanding this
complex system is to characterize it. The dynamics of this process are affected by the
innate and the adaptive host immune system, density-dependent differentiation of the
parasite, the probability of switching to different members of the genomic archive, and
the relative fitness of individual parasites, at the very least. Nearly all of the studies on
VSG switching rate and VSG switching outcomes have measured less than ten VSGs, for
which either the sequence of the VSG gene was known or antibodies against the VSG
existed47,79,80,87,88. Even more recent work cloning hundreds of VSGs over the course of
infection64 could only detect the handful of variants present at any given time, though
they suggest this was an underestimate.
In this thesis I describe the development and application of a high-resolution
method for measuring VSG expression in vivo. I have used this approach to describe the
dynamics of antigenic variation during infection, which should provide a foundation upon
which to better understand the mechanisms driving this process.
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CHAPTER 2. Development of a broadly applicable method for quantifying VSG
expression
	
  
2.1 Introduction
Given the limitations of existing methods for quantifying and identifying VSGs
expressed in a population of parasites, I sought to develop a new method that could both
identify and measure expression of VSGs in parasite populations. Ideally, the method
would identify any VSG, as compared to methods relying on anti-VSG antibody which
limit analysis to one or a few antigenic types49,88,89 and would be quite sensitive, so that it
could be applied to the small parasite samples available from natural infections, for which
parasitemia is often extremely low115. Furthermore, such a method would ideally be able
to identify any VSG, including mosaic VSGs, the novel recombinants that arise during
infection through segmental gene conversion and are likely to be important for long-term
infection64. Along with its utility in identifying novel mosaic VSGs, a method capable of
identifying any VSG would be useful for the analysis of wild parasite populations, for
which no genomic VSG reference exists.
Given these goals, high-throughput sequencing seemed an ideal approach for
examining VSG expression in parasite populations. Producing hundreds of millions of
reads, high-throughput sequencing is extremely sensitive, quantitative and, in
combination with existing tools for transcriptome assembly116, capable of identifying
expressed VSGs de novo. In this chapter, I describe the optimization of a high-throughput
approach for sequencing VSGs, termed “VSG-seq”, which is quantitative and sensitive,
works on small parasite samples, and does not require a reference genome.
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2.2 Optimization of VSG-seq library preparation strategy
There are many possible NGS approaches one can imagine that could solve the
problems delineated above, and to identify the best approach for preparing VSG-seq
sequencing libraries, I compared four possible protocols (Figure 2.1). Each protocol was
designed to identify which aspects of the preparation were important for maintaining
accuracy in quantification while also maximizing sensitivity and efficiency. I prepared
starting material for all library preparations by mixing four T. brucei cell lines, each
expressing a different VSG, in equal proportions. These control samples would allow me
to assess the accuracy of quantification using each method.
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Figure 2.1. Schematic of four library preparation protocols.

The first approach, “oligo-dT”, was used as a baseline for comparison. This
protocol was a typical RNA-seq library preparation in which poly(A) mRNA is isolated
and then fragmented, followed by generation of double-stranded cDNA (dscDNA) using
random hexamers. The dscDNA was then used as the input material for an Illumina DNA
sequencing library preparation kit.
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The second approach, “VSG”, tested the degree of enrichment for VSG sequence
accomplished by using a VSG-specific primer for 1st-strand synthesis. As an alternative to
random hexamers, a primer against the conserved 14-mer in all VSG 3’UTRs was used to
prime cDNA synthesis. 2nd-strand synthesis was performed as in the oligo-dT
preparation, followed by enzymatic fragmentation of dscDNA. The fragmented material
was used as input material for the same kit as in the oligo-dT protocol. Ideally this
method would remain quantitative but, because the majority of sequenced material would
be VSG mRNA, increase sensitivity.
The third approach, “VSG + SL 2nd Strand”, tested whether an alternative 2nd
strand synthesis protocol, in which 2 rounds of VSG-specific PCR were performed to
create dscDNA, could increase sensitivity even further. This method might also increase
the proportion of reads coming specifically from full-length VSG mRNAs.
The final protocol, “Amplicon”, tested whether simply sequencing VSG cDNA
amplicons could increase sensitivity and enrichment for VSG sequence without
compromising quantification. This protocol used the same VSG-specific primers as in the
previous method, but increased the number of cycles of VSG PCR to 35.
100bp single-end sequencing was performed on all prepared libraries, and VSG
expression was measured by aligning reads to a reference genome made up of only the
sequences of the VSGs mixed in the control populations. The number of reads aligning to
each VSG was then counted. To calculate the percent of the population represented by
each VSG, which should be 25% in all cases, the proportion of reads aligning to each
VSG was divided by the total number of reads aligning to any VSG. It is important to note
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that, because reads were aligned to a reference of only four genes, this analysis did not
assess any possible noise or mapping issues that could result from VSG-seq analysis.
This analysis revealed that all approaches were fairly quantitative (Figure 2.2A),
showing values within 2-3 fold of the actual representation of each VSG. This variability
could be due to variations in expression levels between individual VSGs or BESs,
although the variation observed for each VSG was not consistent between protocols. This
experiment was performed without replicates, however, so it is hard to interpret such
variation. Overall, no method appeared significantly more biased than the others in terms
of quantification.
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Figure 2.2. VSG expression levels and enrichment measured by each protocol.
(A) Graph showing VSG expression measured by each method. (B) Graph showing the
total number of reads and number of reads aligning to VSG in each preparation. (C)
Graph showing enrichment for VSG sequence, relative to standard mRNA-seq, in each
library.
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2.2.1 Enrichment for VSG sequences
Because I observed little bias in quantification of VSG expression between
methods, I chose to investigate whether enrichment for VSG sequence varied between
library preparations. This was important for two reasons: (1) increased sequencing depth
could improve sensitivity; and (2) enrichment for VSG would imply fewer “wasted” nonVSG reads, providing more information per sequencing run and potentially allowing a
higher degree of multiplexing per sequencing lane.
Both “VSG” and “oligo-dT” showed a very small proportion of reads mapping to
VSG (Figure 2.2B&C). Approximately 1% of mRNA sequence is VSG mRNA, which is
expected given the high level VSG expression required in bloodstream form cells. Using
only a VSG-specific primer for reverse transcription did not result in significant
enrichment for VSG sequence. However, using a combination of this primer and a primer
against the spliced-leader sequence resulted in the majority of reads mapping to VSG
(Figure 2.2B). When compared to the proportion of reads mapping to VSG after the
“oligo-dT” protocol (Figure 2.2C), “VSG + SL 2nd strand” increased enrichment to over
40-fold, while amplicon sequencing increased enrichment to nearly 70-fold.

2.2.2 Read coverage across VSG genes
Another concern in developing VSG-seq, besides enrichment for VSG sequence,
is VSG sequence coverage. While enrichment can be high, this does not guarantee that
coverage is uniform. Because one of the goals of VSG-seq was de novo assembly of
VSGs, good coverage of each VSG is critical; otherwise, it would be impossible to
reconstruct full-length VSG sequences. The reconstruction of full-length transcripts is
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particularly important in the case of VSGs, because the 3ʹ end of the VSG, from which
VSG is reverse transcribed, is the more conserved end of the VSG, and a reference
database composed of 3ʹ VSG fragments would severely underestimate the extent of VSG
diversity in any sample. While reverse transcriptase may be processive enough to
transcribe full-length VSG, the efficiency of this reverse transcription in the case of VSGs
is unknown. To examine this, read coverage was visualized in Integrative Genomics
Viewer (IGV)117,118, which visually depicts the mapping of each read to the reference
genome (Figure 2.3). Only the PCR-based approaches showed unbiased coverage, further
supporting the use of these methods for VSG-seq. Because amplicon sequencing would
allow for the sequencing of the smallest samples, it was chosen for further analysis and
optimization.
In summary, I tested four different protocols, and chose an amplicon sequencing
approach based on the following attributes: (1) Enrichment. Amplicon sequencing
provided the most VSG sequence per library; (2) Coverage. Amplicon sequencing
provided uniform read coverage across the entire VSG transcript; (3) Quantification.
Amplicon sequencing was similarly accurate in quantification to the other methods
tested; and (4) Input requirements. Amplicon sequencing required the smallest amount of
starting material, because VSG cDNA is amplified by PCR during the library preparation
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Figure 2.3. Read coverage across VSG transcripts.
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coverage(top) for the protocol noted.
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2.3 Optimizing VSG-seq analysis: mappability
After identifying VSG amplicon sequencing as the best approach for VSG-seq, I
optimized the analysis parameters for this approach. In the previous analysis, sequences
were only mapped to a reference genome containing VSGs known to be in the sample.
This simplified quantification, but ignored a major issue with sequencing VSGs:
mapping. Portions of VSG sequences are frequently very similar or identical26, such that
it is likely that a given 100-bp read cannot map uniquely to certain regions within the
VSG it arose from. Uniquely mapping reads are required for accurate quantification of
expression, however, and quantification of multiply mapping reads (without the aid of
some complicated analysis algorithms that have not yet been developed) will always
result in the over- and/or underestimation of VSG expression.
An analysis of the annotated Lister 427 VSGnome reference confirmed that
mapping is a concern when analyzing VSG sequences. To assess the “mappability” (the
proportion of reads which can uniquely map) of the VSGnome, 100bp reads were created
from each reference database, representing all of the possible reads that could result from
each VSG sequence. These simulated reads were then mapped back to the reference,
allowing for only uniquely mapped reads with no more than 2 mismatches per read. A
number of databases were analyzed, using different sets of VSGs, and the mappability of
each VSG was calculated by dividing the number of reads mapping to that VSG by the
number of reads that would map to the VSG if its sequence were completely unique. For
example, if only 50% of the sequence of a VSG is unique to that VSG, that variant will be
50% “mappable”. This analysis shows that as the number of VSGs in a reference database
increases, the mappability of the VSGs within that database decreases (Figure 2.4). A
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simple count of reads mapping to each VSG, then, will result in an underestimate of
expression for VSGs that are less unique and an inability to quantify the expression of
VSGs that have no unique sequence at all.
To assess the degree to which mappability affects quantification in a real
sequencing experiment, I aligned the sequences generated from the amplicon sequencing
library described earlier in this chapter to the Lister 427 reference VSGnome and
quantified abundance either using cufflinks119, an algorithm with little correction for
mappability, or MULTo120, a program specifically designed to correct for the mappability
of each gene. This analysis shows that correction for mappability does indeed affect
expression measurements generally (Figure 2.5A) and in the case of the specific VSGs in
the control library (Figure 2.5B). Cufflinks, which does not correct for the uniqueness of
each sequence, hugely overestimates the abundance of VSG-2, while it underestimates
VSG-832. These errors are proportional to the mappability of each VSG. Thus, VSG-seq
can only accurately measure VSG expression when a tool to correct for mappability, such
as MULTo, is used. All further analyses, unless otherwise noted, used MULTo for
quantification of VSG expression.
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Figure 2.4. Mappability of different VSG databases.
Histograms showing the mappability (or uniqueness) of VSGs in databases of various
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2.4 Characterizing VSG-seq
After identifying the ideal parameters for preparing and analyzing VSG-seq
libraries, I wanted to assess the final protocol. Specifically, I sought to determine the
sensitivity of the method along with whether the raw number of input cells could affect
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the limit of detection or quantification of VSG expression. To do this, I again prepared
control mixtures of parasites. An outline of this experiment is provided in Figure 2.6.
Briefly, I prepared two sets of mixtures in triplicate, from seven lines, each expressing a
different VSG. In one set (Library A), cells were mixed in ten-fold dilutions, and in the
other (Library B) cells were mixed in equal proportions. After preparing these mixtures,
either 1 million or 10 million cells were used to make VSG-seq libraries. For these
experiments, and all further VSG-seq experiments, a newer, low-input DNA sequencing
kit from Illumina (NexteraXT) was used to make sequencing libraries from VSG
amplicons.
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Figure 2.5. Comparison of quantification using MULTo or cufflinks.
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mixture, and the gray bars represent quantification for each library using MULTo or
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2.4.1 Assembly of VSGs and relationship to number of input cells
Although previous analyses show that VSG expression could be quantified using
the Lister 427 reference, this reference is useless for analysis of any strain without a
reference VSGnome or for the analysis of expression of mosaic VSGs, because mosaic
variants generated by segmental gene conversion during the course of an infection are, by
definition, absent from any reference genome. Thus, it was critical to test whether a
useful VSG reference could be assembled de novo. I used Trinity, a transcriptome
reconstruction method designed specifically for the reconstruction of alternative
isoforms, for de novo assembly of VSGs116. I reasoned that this tool might be suitable for
the reconstruction of VSG transcripts, which often share many stretches of homology,
especially in the case of mosaic VSGs. I tested Trinity’s assembly using Library A in
order to determine whether assembly required some level of coverage for accurate
reconstruction of a VSG transcript. This analysis revealed that Trinity could successfully
assemble full-length or nearly full-length VSG sequences from as few as nine cells in the
control mixture (Figure 2.7). It is important to note that Trinity also assembled VSG
transcripts that were not expressed in the control mixtures, which probably represent
transcriptional noise in each cell.
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Figure 2.7. Efficiency of assembly using Trinity.
Graph showing the fraction of each VSG assembled (mean +/- SD) compared to the
number of cells in the population.

2.4.2 Limits of quantification of VSG expression
After aligning reads to the Trinity-assembled reference genome (in the case of
Library A; Library B was quantified using the Lister 427 reference VSGnome), I
determined that VSG-seq is capable of quantifying a variant’s presence within the
population, for variants present above 0.1% of the population (Figure 2.8A), within a ~25-fold range (Figure 2.8B). VSG-seq could quantitatively detect variants present on
0.01% of parasites; all assembled VSG sequences that were not present in the control
mixtures were measured at less than 0.01% of the population (Figure 2.8C), while
variants present at <0.1% of the control mixture all showed values between 0.01-0.1%.
The apparent overestimation of less abundant VSGs in this control experiment is likely a
result of low-level switching in the more abundant components of the mixture, or lowlevel transcription of silent VSGs. The limits of detection and quantification for VSG-seq
appear to be independent of starting cell number, as control mixtures made from 106 or
107 cells showed similar results.
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Figure 2.8. Quantification of VSG expression in control libraries.
(A) Quantification of VSG expression in control library (mean +/- SD), in which cells
were mixed in ten-fold dilutions. The black bar (“Expected”) represents the proportion of
cells expressing that VSG in each control mixture, and the gray bars represent
quantification for each library using VSG-seq. (B) Quantification of VSG expression in
control library (mean +/- SD) in which cells were mixed in equal proportions. Note that
the analysis of this library was performed using the Lister427 VSGnome database, rather
than an assembled reference genome. (C) VSG expression calculated for VSGs absent
from the control mixture in Figure 1 (mean +/- SD). Although some VSGs are assembled
and quantified below 0.01%, these do not appear to correspond with VSG protein in the
population. The single point above 0.01% is likely the result of a parasite that has
undergone switching in one replicate, as this VSG is expression-site associated and is
frequently switched to in this strain.
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2.5 Discussion
These experiments demonstrate that VSG-seq is both quantitative and sensitive.
The optimized method, based on sequencing of VSG amplicons, maintains accuracy in
quantification even after 35 cycles of PCR, so even very small samples can be analyzed.
Most importantly, the approach relies on de novo assembly of VSG transcripts from
sequencing reads to identify VSGs present in a parasite population. This approach, an
alternative to methods relying on anti-VSG antibodies, can be applied to any sample,
regardless of one’s knowledge of the parasite’s genomic VSG repertoire.
Of course, there are aspects of this method that can complicate analysis and which
are important to keep in mind when analyzing VSG-seq data. First, the limit of detection
of VSG-seq is neither a number of cells nor a number of reads, but rather a proportion of
the sample of parasites analyzed. This is likely due to transcriptional noise in every cell.
In these control samples, at least, it is likely that this noise arises from similar genomic
sources (silent BESs or chromosome-internal VSGs which fall near a promoter are
possibilities) and these transcripts are present at a level of about 1 per 10,000 VSG
transcripts. Thus, when analyzing a sample of 106 parasites, any VSG present on less than
100 parasites will not rise above the level of this noise. This is unfortunate, because these
extremely rare variants could be extremely interesting biologically. An approach that
could determine VSG expression in individual cells, such as single genome sequencing121,
could be used to determine the precise level of transcriptional noise in individual
parasites. Another complicating aspect of this detection limit is that smaller samples
(<10,000) allow, in theory, for detection of all variants. These control experiments only
tested samples isolated from 106 parasites; further characterization of libraries made from
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smaller numbers would be beneficial to understanding the limitations of VSG-seq. In
patient samples, for example, which may only contain hundreds of parasites, an
understanding of the limits of detection for library preparations made from small samples
may be critical to interpretation of VSG-seq data.
Another aspect of this method that is important to consider is the issue of
mappability. Quantification relies on corrections for mappability but in cases where sets
of VSGs are very similar, there may be no unique region of certain VSGs and no
straightforward way to correct for this. Although this has not been a major issue in my
experiments, in some situations, perhaps later in infection when mosaic VSGs dominate,
this could be an important consideration for accurate VSG-seq analysis.
Along these same lines, read mapping can limit the diversity detectable within a
population. Due to the error rate of high-throughput sequencing122, it is typically to allow
read mapping with mismatches. To effectively map reads to assembled VSGs, this
analysis requires that assembled VSGs sharing >98% sequence identity be “collapsed”
into one representative VSG sequence. Thus, some degree of diversity at the nucleotide
level can be lost during this analysis. An alternative approach would be to allow no
mismatches during read mapping, but this could compromise the sensitivity of the
approach.
Overall, however, these experiments have shown that VSG-seq works well on
samples isolated from in vitro cultures. In the next chapter, I will examine the feasibility
of the technique when applied to samples collected from the blood of infected animals.
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CHAPTER 3. VSG expression during acute T. brucei infection

3.1 Introduction
After optimizing VSG-seq in vitro, I next piloted the approach in samples
collected from mice infected with the well-characterized but highly virulent Lister 427
strain of T. brucei. This strain was chosen because we have some knowledge of its
switching behavior in vitro, to which in vivo results can be compared49,54. Although the
Lister 427 strain has been well characterized in vitro, little is known about antigenic
variation in the strain in vivo. The strain was ideal for a pilot experiment because the
Lister 427 reference VSGnome could be used to validate assembled VSGs. This pilot
experiment would demonstrate the applicability of VSG-seq to samples collected from
animals, in addition to possibly providing new information about this strain’s switching
behavior in vivo.

3.2 Infection dynamics vary between mice
For this pilot, five Balb/cByJ mice were infected intraperitoneally (i.p.) with ~5
wild-type Lister 427 parasites expressing VSG-2. Five parasites were used to initiate
infection in order to keep infections clonal, so that any variants detected at later times
would represent true switch events and not the outgrowth of a rare variant present upon
infection. Indeed, in experiments described in Chapter 6, I found that an increased
parasite inoculum does appear to increase observed diversity. Parasitemia in tail blood
was monitored daily by hemacytometer. Once parasitemia was detectable, parasites were
collected by submandibular bleed. The vast majority of red blood cells (RBCs) were
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removed from each sample using magnetic-activated cell sorting (MACS) with antiTer119 beads, which I determined to be a better method for smaller numbers of parasites
than the DEAE cellulose protocol used extensively in the past123.
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Figure 3.1. Parasitemia during acute infection.
Graph showing parasitemia in each of five mice during infection, as measured by
hemacytometer. “low” indicates parasites could be detected, but parasitemia was too low
to quantify accurately. Arrows indicate when samples were collected for VSG-seq;
samples were only collected in those mice in which parasitemia was measureable.

The dynamics of infection in each of the five mice varied significantly (Figure
3.1). One mouse never established an infection, which was most likely due to the dilution
of injected parasites, suggesting that these were in fact clonal infections. If, as intended,
the injection of ~5 parasites effectively results in 1-2 parasites initiating each infection,
infrequently a mouse will receive an inoculum containing no parasites and will not
become infected, as seen in this experiment. Two mice (Mice 1 and 5) succumbed to
infection at day 6 p.i., without clearing the first wave of parasitemia, a common
occurrence in infections with this particular T. brucei strain, which reaches high levels of

	
  

42

	
  
parasitemia due to its inability to respond to quorum sensing factors124. Two mice,
however, managed to control infection beyond the first week. Interestingly, one of these
mice (Mouse 2) did not show detectable parasitemia (>105/ml) until day 11. The last
mouse (Mouse 4) showed more typical dynamics, clearing a first peak of parasitemia
around day 6, followed by a second parasitemic peak before succumbing to infection.
These variable dynamics presented an interesting scenario in which to investigate
antigenic variation: do they relate to the repertoire of VSGs expressed in each infection,
or are they related to the individual immune systems of each otherwise congenic mouse?
Although these mice are clonal, their immune systems, and their B cell repertoires in
particular, are highly and divergently polyclonal125.

3.3 Analysis of variants in mice unable to control the first peak of parasitemia
Analysis of the two mice that could not control the first wave of parasitemia
revealed switching behavior similar to what is observed in vitro in this strain. At the end
of both infections, >99% of parasites express the starting variant, VSG-2, and a small
number of parasites, almost all at <0.1%, express 4-5 other VSG types. 7 unique variants
were identified between the two infections, of which two are present in both infections.
Five of these variants are known to be present in a BES32. While the genomic position of
VSG-12 is uncertain, this variant is commonly seen in populations of switchers in Lister
42754,126. Interestingly, a new VSG was assembled from and expressed in both
populations. It is likely that this variant is absent from the Lister 427 reference database
because this database is based on the Lister 427 “single marker” line127, and the cells used
in this experiment were the wild-type line from which the single marker line was derived.
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Figure 3.2. Early VSG expression.
Quantification of VSG expression in Mouse 1 (A) and Mouse 5 (B). Note that the y-axis
is on a log scale and colors do not correspond between graphs.

Overall, the population of switchers in each mouse is quite similar and consistent
with switched populations observed in vitro, suggesting that antigenic variation may not
be influenced by host factors, at least in this strain at this early stage of infection.

3.4 Analysis of first relapse peaks in mice that control infection temporarily
Analysis of the later time points collected from Mice 2 and 4 showed surprising
VSG diversity, at least in contrast to the simplified though prevalent model of switching
in which one or a few variants make up each parasitemic peak. In both infections, 9
variants besides the starting variant, VSG-2, could be detected (Figure 3.2 and Figure
3.3). In total 14 variants are detected between both infections, 5 of which appear in both.
All variants detected appeared in at least one of the infections described in the previous
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section, again demonstrating that switching preferences in this strain in vivo resemble
those observed in vitro, and that switching preference is consistent between infections
even with different dynamics.
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Figure 3.3. VSG expression across initial and first relapse peaks.
(A) Pie charts showing relative expression of each VSG at each time point analyzed in
Mouse 4. (B) Graph showing parasitemia in this infection, with collection times indicated
by an arrow. (C) Line graph showing change in expression in each VSG over time.
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Examining each infection individually reveals a number of other interesting
aspects of VSG expression in vivo. Mouse 4 shows a peak of parasitemia with
approximately the same timing as the peaks in Mice 1 and 5 and, indeed, the makeup of
this peak resembles that of Mice 1 and 5. Analysis of the later time points in this infection
show that the rare variants from day 6 make up the more abundant variants on day 11, in
roughly the same proportions. Interestingly, however, two VSGs appear on day 8 but are
absent from the population on day 11, suggesting that there may be some competition
between VSGs in vivo, causing certain variants to fail within a population.
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Figure 3.4. VSG expression in the absence of an initial parasitemic peak.
(A) Pie charts showing relative expression of each VSG at each time point analyzed in
Mouse 2. (B) Graph showing parasitemia in this infection, with collection times indicated
by an arrow. (C) Line graph showing change in expression in each VSG over time.
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Mouse 2 never shows a first parasitemic peak, but nevertheless shows clearance
of VSG-2 by day 12, the first time populations were analyzed. This shows that VSGs can
be expressed and cleared by the host immune system even when parasitemia is very low
or undetectable, and that variants need not be abundant to be cleared.

3.5 Discussion
Overall, these experiments demonstrate that VSG-seq works well when applied to
samples collected from an infected animal. All VSGs assembled matched annotated VSGs
from the Lister 427 strain, and most early variants were BES VSGs, consistent both with
observations in vitro and with the prevailing model of switching hierarchy in T. brucei, in
which telomeric VSGs appear earliest in infection. Moreover, the experiments
demonstrated the power of de novo assembly for identifying VSGs, as a new VSG was
discovered in two infections.
The variation in infection dynamics among the four infections raises interesting
questions about VSG dynamics in vivo. Though all infections were initiated with
genetically identical parasites, control of the infections was quite variable, suggesting that
the host immune system could play a large role in the measureable outcomes of VSG
switching. Specifically, the dynamics observed in Mouse 2 show that some variants may
be cleared even when present in small numbers. This is likely due to the germline B cell
repertoire unique to this mouse125. That is, this Mouse 2 may have had pre-existing
antibodies recognizing VSG-2, resulting in early clearance of this variant and suppression
of the first parasitemia peak. Thus, although switching may occur in a rough order, with
some probability for certain variants to be chosen before others, the observable outcomes
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of switching may be largely shaped by the B cell repertoire of a given host. The dynamics
of this particular infection also emphasize the importance of analyzing parasite
populations even at very low parasitemia. During the time when parasitemia was
undetectable, VSG-2 was cleared and another variant took over as the major VSG within
the population. The dynamics of this process were missed because samples were not
collected during this time.
Despite the variation in infection dynamics between these four infections, all of
the infections have one thing in common: substantial and unexpected VSG diversity,
particularly as infection progressed. However, because these later time points also
represented terminal time points, it remained unclear whether this was a common feature
of antigenic variation in vivo or a consequence of terminal parasitemia at the time of
sample collection. To determine whether this diversity is characteristic of long term T.
brucei infection, which is a more relevant biological context, I next investigated VSG
expression dynamics during infections with a less virulent trypanosome strain that
produces chronic infections in mice.
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CHAPTER 4. VSG expression in vivo during chronic T. brucei infection
	
  
4.1 Introduction
After analysis of acute infections with a virulent strain of T. brucei, it became
clear that a more chronic model of infection would be required to answer questions about
long-term VSG expression dynamics in vivo. Such an infection model is more relevant to
natural infections, which can last months or even years65, and certain aspects of antigenic
variation that may be critical to natural infections, such as the appearance of mosaic
VSGs or the effects of immune system exhaustion on VSG dynamics, are likely only to be
measurable after weeks of infection. To analyze VSG dynamics during a chronic
infection, I used the EATRO1125 strain of T. brucei128,129, which produces infections of
at least 30 days, or approximately 4 parasitemic peaks, in a mouse.

4.2 VSG diversity and dynamics during early infection
To measure VSG expression within populations of T. brucei, I infected four mice
with ~5 EATRO1125 parasites. This strain had originally expressed VSG AnTat1.1 128,129
but was now heterogeneous, such that each infection was initiated with a distinct VSG. I
tracked VSG expression dynamics for 30 days (Figure 4.1 and Figure 4.2; the raw data
produced by these experiments and used for these analyses can be found in the published
version of this work130). A few variants made up the majority of the population at each
time point analyzed, but, surprisingly, each sample also contained many rare variants that
would have been undetectable using previous methods for characterizing VSG
populations. Variants typically persisted for approximately 7 days followed by quick
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clearance from the population, although some variants deviated from this pattern.
Notably, all infections showed great diversity even within parasitemic valleys. VSG-seq
identified an average of 28 variants at each time point analyzed during the first 30 days of
infection (Table 4.1).
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Figure 4.1. Dynamics of VSG expression during early infection in (A) Mouse 1 and
(B) Mouse 2.
Each colored line represents an individual VSG’s presence in the population, while the
black line represents total parasitemia. Only variants present at greater than 0.1% of the
population at that time point are shown. When parasitemia could not be measured by
hemacytometer (<106/ml), parasitemia is artificially set at 105/ml to allow for
visualization of the population. Note that, because there are so many VSGs expressed
during infection, colors are difficult to distinguish; overall, variants do not reappear later
in the same infection. A smooth curve connects points where expression or parasitemia
was measured; these curves are for visualization and do not imply the actual kinetics of
variant expression between points.
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Figure 4.2. Dynamics of VSG expression during early infection in (A) Mouse 3 and
(B) Mouse 4.
Each colored line represents an individual VSG’s presence in the population, while the
black line represents total parasitemia. Only variants present at greater than 0.1% of the
population at that time point are shown. When parasitemia could not be measured by
hemacytometer (<106/ml), parasitemia is artificially set at 105/ml to allow for
visualization of the population. Note that, because there are so many VSGs expressed
during infection, colors are difficult to distinguish; overall, variants do not reappear later
in the same infection. A smooth curve connects points where expression or parasitemia
was measured; these curves are for visualization and do not imply the actual kinetics of
variant expression between points.

	
  

51

	
  

d6
Day
Mouse 1 15
Mouse 2 10
Mouse 3
Mouse 4

d7

9
7

d12
18
34
13
23

d14
21
15
9
17

Number of VSGs expressed
d18 d21 d24 d26 d30
34
36
6
83
33
53
57
36
29
39
22
21
14
30
21
79
39
12
39
25

d96

58

d99 d102 d105

66

30

32

Table 4.1. Variants present during infection.
Table of the number of VSGs present at each time point. Any variants quantified as
greater than 0.01% of the population are included.
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Figure 4.3. Dynamics of VSG expression during late infection (d96-105) for Mouse 3.
Each colored line represents an individual VSG’s presence in the population, while the
black line represents total parasitemia. Only variants present at greater than 0.1% of the
population at that time point are shown. When parasitemia could not be measured by
hemacytometer (<106/ml), parasitemia is artificially set at 105/ml to allow for
visualization of the population. Note that, because there are so many VSGs expressed
during infection, colors are difficult to distinguish; overall, variants do not reappear later
in the same infection. A smooth curve connects points where expression or parasitemia
was measured; these curves are for visualization and do not imply the actual kinetics of
variant expression between points.
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4.3 VSG diversity and dynamics during late infection
One mouse (Mouse 3) survived much longer than the other three (106 days,
compared to 41-72 days), allowing for close analysis of longer-term infection dynamics.
Although in the later stages of this infection VSG dynamics did appear qualitatively
different with variants persisting longer before clearance (Figure 4.3), possibly due to
immune system exhaustion, parasite populations remained diverse, with 30-66 variants
detectable at each sampling (Table 4.1). The increased survival and lower diversity in this
mouse are also likely due to the polyclonal germline B cell repertoire of this mouse125,
rather than the initiating VSG, as VSG identity has not been shown to affect trypanosome
growth rate or induction of the immune response77,131.

4.4 There is a preference for certain VSGs during infection
To see if these infections showed any bias or hierarchy in VSG expression47,78-80, I
compared the VSG repertoires of all four mice during the first 30 days of infection, in
which 192 VSGs were expressed in total. Although each infection initiated with a
different major VSG, the majority of variants (86%) appeared in more than one infection,
and nearly half (46%) appeared in all four infections (Figure 4.4A). 97 VSGs were
expressed in Mouse 3 from days 96-105. I compared later-occurring VSGs with those
expressed early in Mice 1, 2, and 4, and found none in common, even though early
variants from Mouse 3 also appeared frequently in Mice 1, 2, and 4 (Figure 4.4B).
Overall, these experiments revealed striking diversity within each infection, but
surprisingly frequent occurrence of the same VSGs in different infections. Unfortunately,
these experiments cannot be used to address the question of order or hierarchy in
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switching during infection because they each initiate with different VSGs and a
comprehensive assembly of the genomic VSG archive for this strain was not finished at
the time of analysis.

Figure 4.4. Overlap in expressed VSGs across infections.
(A) Intersection of sets of VSGs expressed during early infection (d6-d30). The total
number of VSGs is listed in parentheses below the mouse number. (B) Venn diagrams
showing intersection of VSGs expressed early in infection (VSGs from Mouse 1, 2, or 4
vs. VSGs from Mouse 3, d7-30) and intersection of VSGs expressed early in infection
with VSGs expressed late in infection (VSGs from Mouse 1, 2, or 4 vs. VSGs from Mouse
3, d96-105).
4.5 Many expressed VSGs never establish in vivo
Within these diverse parasite populations, many variants appeared transiently at
low levels. I have termed these ‘minor’ variants. By examining the fate of every VSG, I
found that at any time during the first 30 days of infection about half (53%) of the
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variants present never reach 1% of the population (Figure 4.5A). This mirrored the
observation of failed variants during acute infection described in Chapter 3. The
frequency with which variants failed suggested this could be an important phenomenon
affecting the measureable outcomes of VSG switching, and led to the question of what
determines VSG fitness.

Figure 4.5. Emergence of minor variants during infection.
(A)Minor variants present at each time point (mean +/- SD). A minor variant is arbitrarily
defined as any VSG that never exceeds 1% of the population during the course of
infection in a single mouse. Major variants are any variant that exceeds 1% of the
population at some point during infection. (B) Venn diagram comparing the fates of
VSGs appearing in all four infections.

To investigate the possibility that certain VSGs, when expressed, conferred some
intrinsic fitness to parasites within the population, I compared the fates of VSGs that
appeared in all four infections. Of the 48 VSGs that appeared in all infections, few were
consistently dominant and few were only ever expressed as a minor variant (Figure
4.5B). This implies that variant success is not determined by the expressed VSG alone.
Instead, variant success is likely to be determined by interactions between the parasite
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and the humoral immune response in each animal. However, there were a handful of
VSGs that were consistently either major or minor. It is possible that these variants do
confer some fitness advantage or disadvantage that overcomes the effects of immune
cross-reactivity or the germline B cell repertoire.

4.6 Detection of mosaic VSGs
T. brucei’s genomic VSG repertoire consists of a high proportion of incomplete
VSG genes or pseudogenes26,27. Indeed, the 289 VSGs observed in these infections may
represent over half of the complete VSG repertoire (~400 complete and predicted to be
functional VSGs for the Lister427 strain26, and ~500 for EATRO1125, according to a
recent assembly of the VSGnome for this strain completed in collaboration with George
Cross). The 65-135 VSGs observed before day 30 could represent up to one-third of the
pre-existing repertoire. Thus, there is pressure on the parasite to diversify its genomic
repertoire to sustain infection, namely by the formation of mosaic VSGs.
Though previous studies had noted that mosaics tend to arise later in infection, or
at least after about 3 weeks of infection in a mouse, they did not determine when these
variants form within the genome, or how61,64,76. It is unknown whether mosaic VSGs form
at the active expression site or within the silent repertoire prior to expression. To identify
possible mosaics, I compared expressed VSG sequences to two independently assembled
genomes for this parasite graciously made available by Keith Matthews and Isabel Roditi.
Because of limitations in the amount of material available at each time point, I could
choose only a few candidates for validation. Candidate VSGs were identified based on
three criteria: (1) <80% of the VSG length aligned to any sequence in either genome,
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which suggested a novel variant absent from the parent genome; (2) the VSG was
expressed in only one infection, which provided evidence the VSG resulted from a novel
recombination event; and (3) the VSG was expressed at >0.1% of the population,
meaning it would be more easily detected by PCR. To test that these were true mosaics
and to determine when they formed within the genome, I used VSG-specific primers to
confirm their absence from the genome of the parental strain and presence within gDNA
collected during infection. I identified three mosaic VSGs using this approach. In each
case, the mosaic VSG was only detectable by PCR when it was also being expressed
within the parasite population (Figure 4.6). With the caveat that parasites were not
sampled daily, this suggests that mosaic formation occurs, at least in these cases, shortly
before expression with subsequent transposition into the active expression site, or directly
within the active expression site.
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Figure 4.6. Identification of mosaic VSGs.
(A) Transient expression of a mosaic VSG in the population, and PCR confirmation of the
mosaic is shown below. The black line represents total parasitemia at each day post
infection, and the green line represents the number of parasites expressing the mosaic
VSG. “n.q.” (not quantifiable) indicates that the VSG is detectable within the population,
but not quantifiable. “n.d.” indicates that the VSG is not detectable within the population.
Below the graph are products from PCR of gDNA at each time point, using either primers
specific for the mosaic VSG or the control gene, ura3. This VSG could not be amplified
when first detected by VSG-seq, likely because of low cell numbers in the DNA sample
(probably less than 10 cells). (B) and (C) depict mosaics from late infection with PCR
confirmation of the mosaic shown below.
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4.7 Discussion
My results indicate that VSG switching does not occur at a rate just sufficient for
immune evasion, with only a few variants present at any time. Instead, as suggested in the
previous experiments in acute T. brucei infections, high VSG diversity seems to be a
universal aspect of infection that persists throughout infection. This was suggested
previously but never measured directly64. In contrast to experiments in the Lister 427
strain, however, diversity in EATRO1125 infections appears to be much higher. Whereas
9 VSGs were observed at the first relapse peak in acute infections, an average of over 28
variants were observed at any point during a chronic infection. It is hard to say whether
this difference in diversity is meaningful, as only a handful of mice have been analyzed
so far for either strain, but the difference could be due to differences in switching rates, as
it has been suggested, though never concretely quantified, that pleomorphic parasite
strains producing chronic infections switch at a higher rate than lab-adapted strains88.
Beyond simple VSG diversity, antigenic similarity between VSGs may result in
the quick elimination of certain variants by cross-reacting antibodies, rendering such
variants useless, and making the effective VSG repertoire even smaller than the intact
genomic repertoire would suggest. Thus, recombinatorial mechanisms that expand the
pre-existing VSG repertoire may be critical for sustaining a chronic infection, and mosaic
VSG formation is likely necessary to increase repertoire diversity as infection progresses.
My results show that much of the intact VSG repertoire is likely to have been expended
early in an infection, as a result of expression and subsequent recognition by the immune
system. Therefore the pre-existing repertoire of complete VSGs within the genome is
probably insufficient to support the sometimes years-long infections observed in the
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wild65. Although parasitemia is much lower in natural hosts, pre-existing immunity is
common in native mammals132, providing an alternative pressure to diversify the VSG
repertoire.
In addition to highlighting the importance of mosaic VSGs in a chronic infection,
these experiments demonstrate that VSG-seq can be used to successfully identify these
novel variants. More importantly, these experiments give the first mechanistic insight
into mosaic formation. By tracking the presence of a mosaic VSG in the genome over
time, I found that mosaic VSGs probably form primarily within the active expression site,
rather than elsewhere in the genome followed by subsequent transposition as a complete
and functional VSG into the BES, because the mosaic VSGs identified were never
detectable at the genomic level before they could be detected at the RNA level. Due to
the lack of a well-annotated reference VSGnome, it was impossible to determine the
patterns of mosaic formation, but this will be an interesting question in the future. Where
did recombination occur in these examples of mosaicism? Based on the location of the
primers used for confirmation, it appears that all of the mosaic VSGs identified formed
through recombination in the 3ʹ end of the VSG. This mechanism of mosaicism has been
observed before59,60,63,133 and is referred to by some as 3ʹ donation64. The fact that all
mosaics identified might have formed by this mechanism is interesting, as it suggests that
the majority of recombination events could occur in the presumably shielded C-terminus
of the VSG, which may or may not play a role in immune recognition. What, then is the
purpose of such VSG diversification? It will be interesting to follow up on these
experiments and determine whether the introduction of mutation into the C-terminal
domain of the VSG is ever capable of conferring resistance to host antibody.
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Finally, these experiments revealed a significant preference for parasites to switch
to certain VSGs, another aspect of switching long speculated to be true47,78-80. The
infections described in this chapter, however, were each initiated with a different VSG.
This suggests that preference is at least somewhat independent of the initiating VSG, but
also makes a detailed analysis of order in VSG switching, if any such order exists, very
difficult. A specific investigation of order in VSG switching that takes advantage of an
annotated VSGnome for this parasite strain will be needed to tease out the determinants
of hierarchy in VSG switching.
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CHAPTER 5. Further applications of VSG-seq
	
  
5.1 Introduction
VSG-seq revealed interesting aspects of VSG dynamics in vivo in experimental
mouse infections, but one of the most exciting aspects of the approach is its broad
applicability. It can be used on any T. brucei population, including parasites grown in
vitro, parasites from natural infection, or even parasites within other niches outside of the
bloodstream. A fast, high-resolution approach to profiling any of these populations was
previously unavailable. In this chapter, I will discuss further applications of VSG-seq and
the mechanistic insight these applications can provide.

5.2 VSG switching in vitro
VSG-seq can be used to assess switching outcomes for experiments performed in
culture. Recently, a MACS protocol49 in which parasites are coated in anti-VSG magnetic
beads has been used for isolating populations of switched parasites in vitro. The antibody
used is typically against the dominant or starting VSG in a population, retaining parasites
expressing this VSG on the magnetic column while switched parasites are collected in the
flow-through. The best way to measure switching outcomes in the isolated switcher
population, however, has been through the laborious process of cloning individual
switched cells, followed by sequencing of VSG cDNA isolated from each clone. In
collaboration with Galadriel Hovel-Miner, I tested VSG-seq for measuring outcomes in
an experimental switch population as part of a project investigating the role of 70-bp
repeats in antigenic variation in T. brucei.
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Earlier work from several labs had led to the hypothesis that 70-bp repeats play a
role in antigenic variation. This prevailing, but unproven, hypothesis speculated that these
repeats provided recombinatorial homology that facilitated the "choosing" of a VSG
donor sequence in switching35-38. My collaborator had already determined, using a
number of mutant parasite lines, that this repeat sequence, adjacent to most VSGs, indeed
plays a role in selection of non-BES VSGs during a VSG switch. She found that mutants
lacking the 70-bp repeats at the active BES (Δ70) are restricted in their ability to access
the entire repertoire and switch only to VSGs located at other telomeric BESs (HovelMiner, et al, in submission). Additionally, this Δ70 mutant switched very frequently, at
levels orders of magnitude higher than a wild type strain in vitro. She had determined that
introduction of a minimal repeat, consisting of a 70-bp repeat dimer, reduced levels of
switching to wild type levels, whereas a reversed dimer sequence at the active BES
switched as frequently as a Δ70 mutant. The key experiment to demonstrate the role of
this repeat with respect to VSG donor selection, however, needed to show that a dimer
allowed access to the non-BES archive, while a reversed dimer sequence did not.
Previously, this would have required additional rounds of laborious cloning and
sequencing of individual VSGs after isolation of the switched population by MACS.
VSG-seq enabled us to assess repertoire access by the two mutants in a faster, less
biased, and higher-resolution way. I applied VSG-seq to switched populations isolated by
MACS from biological triplicates of each line to determine the switching outcomes for
each. I observed that the line lacking repeats in the active BES (Δ70) could occasionally
select VSGs from sites other than BESs (Figure 5.1). This was in contrast to previous data
using cloning to identify switching outcomes, which showed absolutely no selection from
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sites other than BESs, and highlights the increased resolution of VSG-seq. Nevertheless,
introduction of the repeat Dimer resulted in an increase in the number of VSGs selected
when compared with the no-repeat line (average of 18 VSGs in Δ70-ISceI and 35 VSGs in
Dimer). This increase in diversity of VSG selection appears to be due to an increase in
selection of MC VSGs. The Δ70 strain selected 1 MC VSG, whereas the Dimer strain
selected an average of 11 MC VSGs. There was an additional, albeit smaller, increase in
the selection of VSGs arising from undermined loci. In contrast, the strain carrying a
reversed dimer sequence did not result in a significant increase in the selected VSG
repertoire. These data confirmed that two 70-bp repeats at the active BES are sufficient to
allow selection of VSGs from non-BES sites, and that the 70-bp repeat sequence is
required for this selection, as a reversed Dimer sequence prevents the selection of VSGs
outside of BESs. Thus, VSG-seq can facilitate the quick profiling of switching outcomes
towards an understanding of switching mechanisms in vitro.
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Figure 5.1. VSG-seq analysis of 70-bp repeat mutant strains.
Switching outcomes in populations of MACS-isolated switchers from three biological
replicates of Δ70, Dimer, & Dimer Rv are shown in a heat map, where color intensity
reflects the proportion of each VSG in the population. The Lister 427 VSG number and its
predicted genomic location are shown on the right. “var” indicates that the assembled
VSG sequence had minor sequence variations from the most similar 427 reference VSG.
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5.3 Antigenic variation field isolates
One of my primary goals in developing VSG-seq was to develop a method that
could be applied to T. brucei field isolates. In collaboration with Veerle Lejon and Stijn
Deborggraeve, I tested the feasibility of applying VSG-seq to samples collected from
natural human infections. The samples analyzed were collected from parasitologically
confirmed stage 1 or stage 2 HAT patients in the Democratic Republic of the Congo.
RNA was extracted from 2.5 mL of blood from each patient. An estimate of
parasitemia for each patient was made microscopically by examining the buffy coat of
10ml of blood, and by QPCR134 on the isolated RNA. QPCR was used to infer the
relative parasitemia of samples and did not provide an absolute measure of parasitemia.
All samples analyzed, except for one (RB0017S), showed >50 parasites microscopically.
RB0017S showed 21-50 parasites in the isolated buffy coat, and its relatively lower
parasitemia was confirmed by QPCR. Though sensitive for diagnosis, visual counting of
parasites concentrated in the buffy coat is not particularly accurate for estimating
parasitemia135, and these counts do not indicate a parasitemia of 5 parasites/mL. Rather,
these results show that all patients analyzed presented with relatively high parasitemia for
infection with T. b. gambiense.
The VSG PCR step of the VSG-seq library preparation was somewhat inefficient
in these samples, producing many nonspecific bands. This was probably due to the high
level of host RNA present in each sample, relative to parasite RNA. To improve
enrichment for VSG sequence, an alteration to the library preparation was made in which
PCR products ranging in size from 1kb to 2kb were gel extracted and used as input
material for creating sequencing libraries, rather than using all PCR products.
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This approach appears to have worked, as VSG sequences were assembled from
all five samples analyzed. Analysis parameters were difficult to set, however, due to the
unknown parasitemia in each sample. To be conservative in my analysis, I only counted a
VSG as present within the population if it was present at >1% of the population. In T. b.
gambiense infection, parasitemia can be as low as <100 parasites/mL135, though this is
unlikely given the estimates of parasitemia in these samples. If parasitemia were indeed
<100 parasites/mL, a detection cutoff of 0.1% could result in significant overestimations
of diversity.
Using this relatively conservative cutoff, VSG diversity in each sample ranged
from 2 to 7 VSGs (Figure 5.2A). Using a detection cutoff of 0.01%, which assumes at
least 10,000 parasites per sample or 4,000 parasites/ mL of blood, diversity ranges from 7
to 11 VSGs per sample. This is somewhat lower than observed in mouse infections but
perhaps unsurprising, given the low parasitemia typical of T. b. gambiense infection, and
the likelihood of pre-existing immunity against certain variants in these patients132.
A comparison of expressed VSGs showed some overlap between samples (Figure
5.2B). RB0011S and RB0030S contain the same two VSGs, and one VSG is in common
between RB0011S, RB0017S, and RB0030S. Interestingly, there was no overlap between
RB001S or RB002S and the other samples.
It is important to consider the relationships between each sample when
interpreting the overlap in expressed VSG repertoires. RB001S and RB002S came from
the same village around the same time, while RB0011S and RB0017S were isolated
around the same time in the same clinic. RB0030S was the outlier in this set, collected far
from the other samples. With respect to time, all samples were collected within a one-
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month period. The overlap between VSG repertoires is interesting considering the
relationships between these samples; those with the most in common are not necessarily
those with any temporal or geographic relationship.

Figure 5.2. VSG-seq analysis of human T. gambiense infections.
(A) Pie charts showing VSG expression in each sample, using a 1% detection cutoff.
Colors in each chart represent the same VSGs, with the exception of the chart for Patient
RB001S (*), which was analyzed separately and has no VSGs in common with the other
samples. (B) Venn diagram showing overlap in VSG repertoire between patients
RB002S-RB0030S.
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Analysis of the identity of VSGs expressed in each sample also revealed
something unusual: the most abundant VSG identified in patient RB0017S is identical to
a common BES-associated Lister 427 VSG, VSG-11. Using less strict analysis
parameters, this VSG also appears in RB002S (0.02%) and RB0030S (0.7%). No other
common VSGs were identified in this analysis. The significant overlap in expressed VSG
repertoires between these infections may provide hints at both the diversity of VSG
repertoires between parasite subspecies as well as the extent of the expressed VSG
repertoire in the wild.
There is of course, a major caveat to these observations, which is that it is not yet
clear whether using such small starting samples affects quantification. In these samples,
the amount of parasite RNA is low, and host RNA is in significant excess. Control
experiments, along with possible optimization of the method, will need to be performed
to show that high levels of contaminating RNA do not affect quantification. Although
more experiments are needed to shore up these findings, they suggest not only that VSGseq will work on samples isolated from natural infections, but also that there are
interesting things to be found in wild T. brucei populations. The genomic repertoire has
been compared between some species and subspecies of African trypanosome136,137 but
not the expressed repertoire, which these data show may be distinct and important.

5.4 Antigenic variation in extravascular parasite populations
Finally, VSG-seq provides the opportunity to investigate parasites beyond those
found in the bloodstream of the host. Even in the earliest days of T. brucei research, it
had been recognized that parasites could be sequestered in specific tissue niches, the
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central nervous system (CNS) in particular, where they could be protected from
chemotherapy, to later re-enter the bloodstream and re-establish infection138,139. Although
it had been thought that T. brucei existed primarily in the bloodstream until late in
infection, when it invades the CNS and neuropathology appears in patients, recent work
in mice shows that parasites invade extravascular sites throughout the body after only 6
days of infection. In addition to the CNS, parasites can be found in the heart, lung, liver,
spleen, and adipose tissue and, in all cases, parasites are found extracellularly in the
interstitium of these tissues. Surprisingly, by day 28 p.i. this extravascular population
represents the majority of parasites in the mouse (Luisa Figueiredo, in submission).
Parasites residing in adipose tissue have been found to take advantage of novel metabolic
pathways to utilize fat as a nutrient source, while CNS-resident parasites are
morphologically different from the well-characterized bloodstream form T. brucei9. The
unique properties of parasites residing in other tissues have not yet been characterized,
but together these results suggest that the extravascular niche is not simply a side effect
of high parasitemia at the late stages of infection, as once thought. Instead, it is likely that
this niche is an important phase of the parasite’s lifecycle, one that has not yet been
characterized with respect to antigenic variation.
VSG-seq provides an opportunity to examine the expressed VSG repertoire within
extravascular populations. With this in mind, in collaboration with Luisa Figueiredo, I
performed a pilot experiment on samples collected from two mice infected with
EATRO1125 T. brucei expressing the VSG AnTat1.1. One set of samples was collected
from day 6 p.i. and the other from day 28. In both cases, blood was first collected,
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followed by perfusion of the animal with PBS. RNA was isolated from blood and from
brain, fat, heart, and lung. This material was used for VSG-seq.
Analysis of these samples showed the number of VSGs expressed in each tissue
did not correlate with the number of parasites present in that tissue (Figure 5.3A), though
generally diversity was higher on day 28 than day 6, consistent with previous
observations. The number of VSGs expressed in parasites in blood was somewhat higher
than previously observed, but this was likely due to the fact that these infections were
initiated with 5000 parasites, rather than only 5. It is possible, however, that this
difference in diversity is the result of differences in the host mouse strain, as these
experiments were performed in C57Bl/6 mice, rather than the Balb/c mice used in
Chapter 3 and 4.
Comparison of VSG populations in each tissue revealed a complex situation
within the host. On both day 6 (Figure 5.3B) and day 28 (Figure 5.3C) VSGs could be
found that were unique to an individual tissue. Some tissues seemed to contain more
unique VSGs than others but, with only two infections, it is hard to interpret these data.
Nonetheless, the high diversity across tissues can be taken as evidence that this is not
well-mixed system; a simple survey of parasites in the blood is not representative of the
tissue niche.
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Figure 5.3. VSG expression in extravascular spaces.
(A) Scatter plot showing the number of VSGs expressed in each tissue compared to the
number of parasites in the sample analyzed. (B) Venn diagram showing overlap in
expressed VSG repertoire between each tissue on day 6 post-infection. (C) Venn diagram
showing overlap in expresses VSG repertoire between each tissue on day 28 postinfection.
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Comparison of VSG populations in each tissue to those in the blood may hint at
possible roles for this extravascular niche. VSG-seq analysis of perfused tissues on day 6
p.i. showed that while nearly every VSG expressed in other tissues was also present in the
blood, over half of the VSGs identified in the lung were unique to that space (Figure 5.4).
Could the lung be a site for initiating VSG switching or diversification? While the
situation on day 28 of infection was more complicated (Figure 5.4), there was one
striking observation resulting from this comparison: while the initiating VSG (AnTat1.1)
had been cleared from the blood and the heart, it persisted in the brain, fat, and lung. In
fact, the initiating VSG was expressed in 1.4% of all parasites in the brain. Thus, certain
extravascular spaces appear to be immune-privileged, which could be important for
parasite dynamics in vivo.

Figure 5.4. Overlap in VSG repertoire between extravascular spaces and blood.
(A) Venn diagrams showing the overlap in expressed VSGs between each tissue and
blood on day 6 post-infection. (B) Venn diagrams showing the overlap in expressed VSGs
between each tissue and blood on day 28 post-infection.
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5.5 Discussion
These experiments show that VSG-seq can be applied successfully to many types
of samples, and in all cases has the potential to provide insight into the mechanisms of
antigenic variation in T. brucei. My experiments examining the role of 70-bp repeats in
VSG donor selection in antigenic variation confirmed previous observations, but provided
much higher resolution than possible using previous approaches. Moreover, the method is
much less laborious than other strategies for profiling switch repertoires.
Studies of VSG repertoires in wild isolates provide evidence that this approach
could be easily applied to any natural infection. Although some optimization and
validation will be needed, the findings from this small experiment hint at interesting
possibilities. VSGs known to be present in T. b. brucei were found in infections presumed
to be T. b. gambiense. This could suggest co-infection, the transfer of genetic material
between parasites6,7, or that the expressed VSG repertoire is, for some other reason,
somewhat constrained. An understanding of the extent of and limitations on the wild VSG
repertoire could affect our understanding of the epidemiology and molecular biology of
this infection in the wild, as well as our approaches to treatment and prevention of
African trypanosomiasis.
Analysis of parasites in extravascular spaces in experimental mouse infections
reveals a new aspect of T. brucei antigenic variation. Based on these data, is it clear that
the population in the bloodstream of an animal is not representative of the entire parasite
population in vivo. This could have significant implications for parasite biology. For
example, the presence of many unique variants in the lung early in infection may imply a
role for this site in antigenic variation. The persistence of certain variants after four
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weeks of infection indicates an immune privileged niche in certain extravascular spaces
that could serve as a refuge for switching in vivo. Taken together, the set of experiments
described in this chapter demonstrates the promise of high-throughput methods for
tackling many questions in the field of T. brucei antigenic variation.
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CHAPTER 6. Discussion

6.1 Development of VSG-seq
An understanding of the dynamics of VSG expression and switching is an
important step towards understanding the mechanisms driving immune evasion in T.
brucei infection as well as the host response to VSG. For technical reasons, however, it
has been challenging to measure VSG expression in vivo in a high-resolution way. Some
have tried to address the question of VSG dynamics in other ways, either by mathematical
modeling5,78,81,82,84,85 or by using low-throughput approaches47,64,79,80,87,88. While our
understanding of the genomic VSG repertoire has improved greatly in recent years due to
next-generation sequencing approaches, our understanding of how that repertoire is
accessed in vivo has not yet benefitted from more modern techniques.
To address this gap in our understanding of VSG switching, I developed a nextgeneration sequencing approach, termed VSG-seq, for measuring VSG expression in high
resolution. Based on de novo assembly, the method obviates the requirement for a
reference genome, and allows for the identification and quantification of VSG expression
from any strain of T. brucei. The method, orders of magnitude higher in resolution than
previous approaches, can detect VSGs expressed on as few as 0.01% of the parasites in a
population.
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6.2 Confirmation of existing hypotheses
Using VSG-seq, I profiled VSG expression in both acute and chronic mouse
infections. My results confirmed many predictions made based on low-throughput
studies. Indeed, the predictions made by Hall, et al.64, of an average of 32 and as many as
95 VSGs at any time were extremely accurate: I measured an average of 28 and as many
as 83 VSGs expressed as one time. It is telling that these estimates are somewhat higher
than my measurements, as the limit of detection of VSG-seq prevents the method from
sampling every VSG in a population. Moreover, recent work on samples collected from
sleeping sickness patients92 along with my own results from sequencing patient samples
suggest that this VSG diversity is not simply an artifact of the mouse model and may be
clinically relevant.
In line with predictions of a hierarchy in VSG switching, I observed that VSG
populations in chronic infections were distinct at different stages of infection and that
there was a clear preference for expression of certain VSGs during the first 30 days of
infection. Additionally, my work again confirmed the observation that mosaic VSGs
dominate only after the first peaks of infection, as I was only able to detect these variants
on day 18 p.i. or later.
These support previous predictions and lay the foundation for a more in-depth
study of switching hierarchy and order. Because the chronic infections in this study were
each initiated with a different VSG, explicit questions of order could not be addressed. I
hope to address these questions explicitly in the near future, however, by initiating sets of
infections with specific VSGs and comparing the switching outcomes. This of course will
require the generation of a good catalogue of BES-associated and genomic VSGs in the
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EATRO1125 strain. Once generated, such a catalogue can be used to assess the
relationship between VSG order and genomic position. Are the same set of VSGs
switched to no matter what VSG begins an infection, consistent with a model in which
only genomic location matters, or is preference relative to the starting VSG, supporting a
model in which homology in or around the expressed VSG plays a larger role? This
experiment should determine whether hierarchy is independent of initiating VSG, as the
experiment described in Chapter 4, comparing infections beginning with different
variants, suggests.

6.3 New questions about antigenic variation: Minor variants
In addition to lending to support to existing hypotheses, my work brought to light
aspects of infection that could not have been accessed using other approaches. During
infection, many VSGs are expressed at a single time, but most of these variants never
establish to levels at which they could have been detected using low-resolution
techniques. The presence of these minor variants both supports the hypothesis that
immune cross-reactivity plays a role in determining variant order during infection85,86, as
well as the concept that the complete VSG repertoire (~400 VSGs in Lister 427, ~500 in
EATRO1125) is insufficient to support the long T. brucei infections observed in the field.
Many of those 400-500 variants fail too quickly to contribute significantly to immune
evasion. Thus, VSG diversification through the formation of mosaic VSGs or other yet-tobe identified mechanisms may play a more significant role in sustaining infection than
previously appreciated.
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Perhaps most interestingly, the identification of minor variants raises a new
question relevant to understanding VSG expression dynamics: what determines variant
fitness? My data suggest that fitness is not solely intrinsic to the VSG. Although I have
proposed antibody cross-reactivity or the individual host’s unique germ line B cell
repertoire to be factors that determine variant success or failure, this has certainly not
been proven. To address this hypothesis, one could examine, for example, the likelihood
of an individual variant to be minor after the expression of an antigenically similar VSG
during the same infection. If the host immune system is primed to recognize a variant
because an earlier VSG was antigenically similar, that variant should not establish in the
population as successfully as the previously expressed VSG. Addressing this
experimentally would require an understanding of antigenic "classes" of VSG based on
the ability of VSGs that are different in primary sequence to elicit similar antibody
responses. There are only two VSG crystal structures, however, so it is difficult to predict
which variants are likely to be similar at the structural level based on sequence alone.
Currently, little is known about how antibody binds VSG, but patterns of VSG success
and failure in vivo might inform our understanding of the antibody-VSG interaction.
Perhaps pairs of variants in which one frequently “fails” when expressed during the same
infection as the other are in fact structurally and antigenically similar.

6.4 New questions about antigenic variation: The wild VSG repertoire
The identification of minor variants in the bloodstream during infection raised
new questions about the biology of antigenic variation in T. brucei, but the application of
VSG-seq to patient samples and extravascular parasites raised even more. The study of
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field isolates presented in Chapter 5, although quite preliminary, has potentially
interesting implications for the wild VSG repertoire. The expressed repertoire of VSGs in
the field could be important for understanding both parasite ecology as well as host
immunity. My data show significant overlap in expressed VSG repertoires between
geographically distinct infections. Does this mean the expressed VSG repertoire in the
field is actually quite limited? If so, what restricts the repertoire to such a degree? Could
host immunity play a role in the detectable expressed VSG repertoire?
Additionally, my data show one VSG that is expressed in at least one patient, and
possibly three, which is BES-associated in the Lister 427 strain of T. b. brucei. This again
suggests a limited VSG repertoire, but in this case across T. brucei subspecies. Does this
reflect a shared ancestral VSG repertoire, sexual recombination between parasite
subspecies in the tsetse, or coinfection?
Perhaps this limited repertoire is unsurprising. One of the most common HAT
field diagnostics is the card agglutination test for trypanosomiasis (CATT) 135,140,141,
which diagnoses patients based on the presence of antisera against a three VSGs
commonly expressed by parasites in West Africa. Thus, the repertoire regionally appears
to be constrained enough to use the presence of an anti-VSG antibody response for
diagnosis. Interestingly, however, these variants do not predominate throughout Africa,
and one study showed the absence of the gene encoding one of these variants in some
trypanosome strains isolated in Cameroon142. Thus, an understanding of the wild
expressed VSG repertoire and how it changes in different regions could lead to the
development of diagnostics specific for different regions in Africa. Although these data
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are quite preliminary, they suggest there is interesting biology happening in natural T.
brucei infections that will be worth investigating in the future.
Another source of interesting biology in natural VSGs repertoires is in the tsetse
salivary glands. Because only hundreds of metacyclic parasites need to be injected by the
tsetse for transmission143, and these parasites initiate nearly all infection, could there be a
limited inoculating repertoire? Studies of the genomic set of metacyclic VSGs show only
between 5 and 27 metacyclic VSGs in the genome26,144, and another study shows some
evidence that metacyclic VSGs are less likely to rearrange to form mosaic variants,
further limiting this repertoire145. How extensive is the wild metacyclic expressed VSG
repertoire? If the repertoire is in fact limited, this could have dramatic consequences for
therapeutic approaches for HAT, including vaccination.

6.5 New questions about antigenic variation: Extravascular parasites
The study of parasites residing in extravascular spaces in tissues described later in
Chapter 6, though once again very preliminary, has significant implications for our
understanding of antigenic variation in vivo. A surprising number of VSGs are expressed
exclusively in the lung. This suggests that the lung may be a site of early switching and
diversification. If this is the case, it may indicate the existence of a trigger for switching
or diversification unique to that tissue. One such trigger could be oxygen tension, which
is higher in the lung than in other tissues146, and which is known to affect the expression
of a major surface glycoprotein in procyclic forms of the parasite147. Such a hypothesis
could be tested easily by varying oxygen concentrations in parasite cultures and
measuring the effect on antigenic variation. Of course other factors, such as pH, could
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also serve as a trigger for switching. So far, there is no known environmental factor that
can initiate VSG switching, but these data suggest that one might exist.
An alternative explanation for the increased diversity in the lung is the lack of an
antibody response within that tissue, which would preclude specific clearance of any
variants and allow parasites expressing antigenically similar VSGs to survive and grow.
The persistence of early expressed VSGs in certain spaces (brain, fat, and lung) long after
they have been cleared from the blood supports a model in which increased VSG diversity
results from immune-privileged sites in the host. This observation, once confirmed, could
be followed up by a study of the B cell populations and antibody repertoires, both general
and VSG-specific, within each potentially immune privileged tissue. Such experiments
might reveal certain antibody isotypes that are present or absent from each site. For
example, although IgM is thought to be the primary isotype involved in parasite
clearance96, the role of IgM and other isotypes in the context of extravascular spaces is
not known. Thus, it is possible that IgM is required for parasite clearance in tissues and
that early variants persist in certain spaces because the bulky IgM molecule cannot
diffuse efficiently into those spaces. On the other hand, if VSG-specific antibody or B
cells can be detected but parasites expressing that VSG have not been cleared, it may be
that T. brucei modulates the host B cell response in these spaces. Very little is known
about immune privilege or the extravascular B cell response, but sequencing of the
expressed extravascular VSG repertoire may have indirectly shed light on both of these
phenomena.
Moreover, it might be possible to take advantage of immune-privileged spaces, if
they exist, experimentally. Due to antibody cross-reactivity, it is likely that many variants
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never establish in the bloodstream. This may be especially true for mosaic VSGs, which
are more likely to be antigenically similar to a previously expressed VSG, particularly if
they do form in the active BES. The early clearance of cross-reactive or less fit variants
in the blood leads to a skewed view of the VSG population in vivo. Immune-privileged
spaces may provide a better context for studying the mechanisms of switching and VSG
diversification, as all variants would be detected in such sites.
The application of VSG-seq to tissue-resident parasites has hinted at two potential
roles for these spaces. In addition to this, a more extensive study of parasite populations
over time in each space could provide information on the presence of variants in each
niche over time. This kind of data could then be used to create a map of T. brucei’s route
through the tissues of its host, something about which very little is currently known.
Another major unanswered question that would be informed by an extension of these
experiments is whether VSGs have a role in sequestration of trypanosomes in different
physiological niches, as is the case for the var gene family in P. falciparum infection148.
Could certain VSGs be lung- or brain-specific?

6.6 New answers to old questions: Mosaic VSGs
Although many aspects of antigenic variation are informed by this work, nearly
every finding in these investigations points towards one theme: VSG diversification. The
set of expressed VSGs at any given time during is large. Of those many variants, half are
destined to fail. An examination of the parasites in tissues reveals another layer of
diversity. Over and over, it becomes clear that the genomic VSG repertoire alone is
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insufficient to sustain an infection, and the parasite must diversify its VSG repertoire
through the formation of mosaic VSGs.
The idea that VSG diversification is critical to sustaining a chronic T. brucei
infection is certainly not a new one88. Despite the obvious importance of the process, the
mechanisms of VSG diversification in general, and mosaic VSG formation in particular,
have remained elusive and experimentally intractable. VSG-seq, then, presents a new
avenue for tackling this historically difficult question. My investigation of chronic
infections revealed the first temporal data on the formation mosaic VSGs, suggesting that
these novel variants form within the active expression site. The patterns of mosaic
formation suggested by my data also raise interesting questions about the immune
response to VSG. What use could mosaic formation in the buried C-terminal end of the
VSG serve? It will be interesting to investigate whether mutations in the 3ʹ of the VSG
can ever confer resistance to host antibody. The mosaics identified by VSG-seq may be
ideal candidates for such analysis, because they are present at relatively high levels and
should, to some degree, be capable of evading host antibody. Thus, the mosaics
detectable by this method may be not only the variants most relevant to a natural
infection, but also the variants most likely to confer an antigenic advantage in vivo. Thus,
beyond informing antigenic variation in T. brucei, they may provide insight into the
antibody-VSG interaction.
Taken together, my results show that VSG-seq is not only descriptive. Instead,
this approach can provide mechanistic insight into antigenic variation and the creation of
mosaic VSGs. This high-resolution and quantitative technology can now be used to ask
not only whether mosaic VSGs form, but when, where, and how. There is also no reason
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why this approach cannot be applied to other systems, so questions of repertoire
diversification can extend beyond the African trypanosome. Using VSG-seq, I have
shown that high-throughput bioinformatics approaches are key to achieving the highresolution picture of VSG switching needed to understand the mechanisms of antigenic
variation in vivo.
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CHAPTER 7. Methods

7.1 Cell Culture
Control libraries (Chapter 2) were made using mixtures of Lister 427 clones each
expressing a different VSG. Each line has an antibiotic resistance marker at the promoter
of the active expression site and was grown in vitro in HMI-9 with antibiotic selection to
minimize in situ switching. To make the libraries, parasites were counted with a
hemacytometer and mixed in known proportions. RNA was isolated from these mixtures
immediately and used for the preparation of VSG-seq libraries.

7.2 Infections
For infections investigating parasite diversity in blood, female Balb/cByJ
(Jackson Labs) mice were infected intraperitoneally with ~5 parasites (pleomorphic or
monomorphic), and parasitemia was counted every 2 days by hemacytometer. 50–100 µl
blood was collected by submandibular bleed for the isolation of parasites and preparation
of sequencing libraries. Mice were sacrificed when they began displaying pathological
symptoms.
For infections investigating parasite diversity in tissues, 6-10 week old male
C57BL/6J mice (Charles River, France) were infected intraperitoneally with 2000 T.
brucei EATRO1125 parasites. Parasitemia was tracked daily by hemacytometer and
animals were sacrificed on either day 6 or day 28 by CO2 narcosis.
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7.3 Isolation of parasites from blood
Serum was removed from blood samples and saved, and the remaining material
was incubated with Ter-119 microbeads (Miltenyi). Samples were then washed twice in
HMI-9 and applied to a MACS column. The flow-through was collected and these redblood-cell-depleted samples were divided for DNA (10%) and RNA (90%) isolation.
DNA was isolated from a portion of the parasite sample using DNAzol (Invitrogen),
according to the manufacturer’s protocol.

7.4 Isolation of tissue-resident parasites
For experiments examining tissue-resident parasites, mice were immediately
perfused transcardially following euthanasia with pre-warmed heparinized saline using a
peristaltic pump. Approximately 30 mg of each organ was collected into Trizol (Life
Technologies).

7.5 RNA isolation
For all experiments except for the investigation of parasites in human infections
and in mouse tissues, RNA was isolated using RNA STAT-60 (Tel-Test, Inc.), according
to the manufacturer’s protocol.
For experiments examining tissue-resident parasites, RNA was isolated from
perfused tissue samples with Trizol (Life Technologies) according to manufacturer’s
instructions. Blood was isolated before perfusion and RNA was isolated from blood
samples using Trizol LS (Life Technologies).
For human infection samples, samples were collected from parasitologically
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confirmed stage 1 or stage 2 HAT patients in D.R. Congo. 2.5 ml of blood was collected
in PAXgene tubes (Qiagen) in the field, which were shipped and stored at -80°C. RNA
was extracted using a PAXgene Blood RNA Kit (Qiagen).

7.6 VSG-seq Library Preparations for optimization
Four approaches to VSG-seq library preparation were tested, each with slight
variations in the protocol up until the production of fragmented dscDNA. Sequencing
libraries were prepared from this fragmented material using the Illumina TruSeq DNA
Sample Prep Kit v1 (FC-121-1001) according to manufacturer’s instructions. All libraries
were sequenced on an Illumina HiSeq 2000 producing 100bp single-end reads.

Prep 1: “VSG”
For this prep, RNA samples were DNase treated using RQ1 RNase-Free DNase
(Promega). After DNase treatment, samples were cleaned by phenol/chloroform
extraction, and polyA mRNA was isolated using Sera-mag oligo(dT) beads, followed by
first strand synthesis with SuperScriptIII Reverse Transcriptase (Invitrogen) using the
VSG 3’UTR primer (see primers). Double-stranded cDNA was produced by combining
10X Second Strand synthesis Buffer (NEB), 10mM dNTPs (NEB), E. coli DNA Ligase
(NEB), E. coli DNA polymerase (NEB), and RNase H (Invitrogen) for 2.5 hours at 16ºC.
After dscDNA was produced, DNA was fragmented to about 200bp using NEBNext
dsDNA fragmentase (NEB) for 43 minutes at 37ºC.
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Prep 2: “oligo-dT”
This prep, which sequenced all polyA mRNA, rather than just VSG mRNA, was
performed exactly as the “VSG” prep, except that mRNA was chemically fragmented (4
minutes at 94ºC in 30 mM Mg2+) to ~200nt and precipitated, and first-strand was
performed using random hexamers. cDNA was not fragmented with dsDNA fragmentase
after second-strand synthesis.

Prep 3: “VSG + SL 2nd Strand”
This protocol was performed as the “VSG” preparation above except, in place of the
second-strand synthesis step, 2 cycles of PCR were performed, using Phusion polymerase
(New England Biolabs) and the SL and SP6-14mer primers (see primers), to specifically
produce double-stranded VSG cDNA.

Prep 4: “Amplicon”
This sequencing preparation was identical to the “VSG + SL 2nd Strand” preparation,
except 30 cycles of PCR, rather than 2 cycles, were performed.

7.7 Optimized VSG-seq library preparation
RNA samples were DNase treated using RQ1 RNase-Free DNase (Promega).
After DNase treatment, samples were cleaned by phenol/chloroform extraction or using
AMPure RNAClean XP beads (Agencourt), and first strand synthesis was performed
using SuperScript III Reverse Transcriptase (Life Technologies), using a primer specific
for the conserved 14-mer in the VSG 3´-UTR (see primers, all-VSG-3´-UTR). 1st strand
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products were cleaned up using AmPureXP beads (Agencourt). 22 cycles of PCR (or 35
cycles in the case of human infection samples), using Phusion polymerase (New England
Biolabs), was performed to amplify VSG cDNA, using SL and SP6-14mer primers (see
primers). PCR products were cleaned using AmPureXP beads and DNA concentration
was measured using a QuBit HS DNA kit (Life Technologies), according to
manufacturer’s protocol. Libraries were prepared from VSG PCR products using the
Nextera XT DNA Sample Prep Kit (Illumina), according to the manufacturer’s protocol.
For control libraries in Chapter 2 and acute and chronic infections described in
Chapters 2 and 3, 100bp single-end sequencing was performed on an Illumina HiSeq
2000. For libraries described in Chapter 5, made from tissue samples, parasites isolated
from in vitro cultures, and human infection samples, 150bp single-end sequencing was
performed on an Illumina NextSeq 500. For human infection samples described in
Chapter 5, libraries were prepared with one alteration to the protocol described above.
Because of the amount of contaminating host RNA and very low parasitemia, PCR
products between 1-1.5 kb were isolated by gel extraction using a QiaQuick Gel
Extraction kit (Qiagen), after the amplification of VSG cDNA. 150bp paired-end
sequencing was performed on these libraries by an Illumina MiSeq (for sample RB001S)
or an Illumina NextSeq 500 (for all other samples).
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7.8 VSG-seq Analysis
Adapters were trimmed using trim_galore(v0.3.3) and SP6 sequences (from VSG
PCR step) were trimmed using cutadapt(v1.3)149.
Because many VSGs show stretches of homology, quantification of expression
can be complicated, whether allowing unique or multiply mapping reads during
alignment. To address this issue, I used MULTo (v1.0) to create a mappability file for
each reference genome120. Sequencing reads were aligned to the reference genome (either
assembled or the Lister 427 VSGnome reference at http://129.85.245.250/index.html),
using bowtie (v1.0.0)150 allowing only uniquely mapping reads and no more than two
mismatches per read (-v 2 –m 1). Then, MULTo’s rpkmforgenes.py was used to calculate
the FPKM value for each VSG. The percent of the population expressing each VSG was
calculated by dividing the FPKM for a VSG by the total FPKM. The number of parasites
expressing a VSG was calculated by multiplying the total number of parasites by the
percent of the population expressing that VSG.
When a reference VSGnome was assembled, sequencing reads were assembled
using Trinity 116 using --normalize_reads. Once libraries were assembled, in-house
scripts were used to identify contigs with an open reading frame (ORF) of >900bp (where
an ORF is identified as start codon to stop codon, or start codon to end of contig). These
ORFs were then compared against the Lister 427 reference VSGnome
(http://129.85.245.250/index.html) using BLASTn (v2.2.28+), and ORFs with an
alignment with an e-value < 1e-10 were considered VSGs. These ORF sequences were
then merged using cd-hit-est (cd-hit v4.6.1)151,152 with the following parameters: -c 0.9 -n
8 -r 1 -G 1 -g 1 -b 20 -s 0.0 -aL 0.0 -aS 0.5.
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These potential VSG sequences were then evaluated by hand using NCBI’s
BLASTn nr/nt database. Sequences that matched chromosomal sequences or non-VSG
genes were removed.
Because some VSG sequences were very similar, and the alignment program
bowtie150 cannot distinguish VSGs >98% similar in sequence using the described
alignment parameters, sequences were then merged again using cd-hit-est (-c 0.98 -n 8 -r
1 -G 1 -g 1 -b 20 -s 0.0 -aL 0.0 -aS 0.5). This final merged contig file represents the final
reference genome for each experiment.
For analysis of 70-bp repeat modified strains (Chapter 5), assembly and
quantification was performed as described above, followed by a comparison to the Lister
427 reference database: assembled VSG sequences, when compared to the most similar
427 VSG, were identified as the 427 VSG when they had either 100% identity over >99%
of the length of the assembled ORF or >99% identity over 100% of the assembled ORF.
Otherwise, assembled VSGs were referred to as variants of the most similar Lister 427
VSG. After identifying the corresponding 427 VSG, noise (VSGs measured below the
limit of detection, 0.01%) and contamination (the starting VSG, 427-2) were removed.
The relative abundance of each remaining expressed VSG was then calculated using its
measured FPKM. These data were then used to create a heatmap using heatmap.2 from
the gplots package in R (https://cran.r-project.org/web/packages/gplots/gplots.pdf).
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7.8 Mosaic Identification
Candidate mosaics were identified by comparing VSG sequences to two
independently assembled genomes for this strain, which were kindly provided by Keith
Matthews and Isabel Roditi. Candidate mosaics were VSGs with <80% of their length
aligning to any sequence in either genome, and expressed in only one infection at >0.1%
of the population. Primers were designed around the likely region of recombination (see
primers) and PCR was performed using HotStarTaq (Qiagen). Mosaic amplicons were
cloned using a Topo-TA cloning kit (Invitrogen) and sequenced to confirm validation.

7.9 Primer sequences
Primer
SL
SP6-VSG14mer
All-VSG-3´UTR
TbURA3F
TbURA3R
c5477_g4_i1_d24-F
c5477_g4_i1_d24-R
c754_g1_i2_d105-F
c754_g1_i2_d105-R
370_g1_i1_d102-F
370_g1_i1_d102-R

Sequence (5´ 3´)
ACA GTT TCT GTA CTA TAT TG
GAT TTA GGT GAC ACT ATA GTG TTA AAA TAT ATC
GTG TTA AAA TAT ATC
CGG CAG CAG TTC TCG AGT
TGG CGT GTA CCT TGA GGC
GGA ATC ACA TCG CGG TTC CCA AAG
CAA TTT TGC CAT CTG CCC CTC CTG
CTT CGA GAC GAC ACC AAA AGC CAC
GGC CGC AAA TGC AGA AGA AAC CAT TAG
GTA AAC TTG AAC CGG CGG TGG C
CAG AGC ACT TTT TGG CAT CGG AGT T

Table 8.1. Primer Sequences.
Table of all primer sequences used for library preparations and mosaic VSG validation.

	
  

94

	
  
REFERENCES
1. World Health Organization. Working to overcome the global impact of neglected
tropical diseases: first WHO report on neglected tropical diseases. Geneva : World Health
Organization; 2010.
2. Simarro PP, Cecchi G, Franco JR, Paone M, Diarra A, Priotto G, Mattioli RC, Jannin
JG. Monitoring the Progress towards the Elimination of Gambiense Human African
Trypanosomiasis. Matovu E, editor. PLoS neglected tropical diseases.
2015;9(6):e0003785.
3. Lai D-H, Hashimi H, Lun Z-R, Ayala FJ, Lukes J. Adaptations of Trypanosoma brucei
to gradual loss of kinetoplast DNA: Trypanosoma equiperdum and Trypanosoma evansi
are petite mutants of T. brucei. Proceedings of the National Academy of Sciences of the
United States of America. 2008;105(6):1999–2004.
4. Reuner B, Vassella E, Yutzy B, Boshart M. Cell density triggers slender to stumpy
differentiation of Trypanosoma brucei bloodstream forms in culture. Molecular and
biochemical parasitology. 1997;90(1):269–280.
5. Macgregor P, Savill NJ, Hall D, Matthews KR. Transmission Stages Dominate
Trypanosome Within-Host Dynamics during Chronic Infections. Cell Host and Microbe.
2011;9(4):310–318.
6. Gibson W, Peacock L, Ferris V, Williams K, Bailey M. The use of yellow fluorescent
hybrids to indicate mating in Trypanosoma brucei. Parasites & vectors. 2008;1(1):1.
7. Peacock L, Ferris V, Sharma R, Sunter J, Bailey M, Carrington M, Gibson W.
Identification of the meiotic life cycle stage of Trypanosoma brucei in the tsetse fly.
Proceedings of the National Academy of Sciences of the United States of America.
2011;108(9):3671–3676.
8. Seed JR, Effron HG. Simultaneous presence of different antigenic populations of
Trypanosoma brucei gambiense in Microtus montanus. Parasitology. 1973;66(2):269–
278.
9. Mogk S, Meiwes A, Boßelmann CM, Wolburg H, Duszenko M. The lane to the brain:
how African trypanosomes invade the CNS. Trends in parasitology. 2014;30(10):470–
477.
10. Bentivoglio M, Kristensson K. Tryps and trips: cell trafficking across the 100-yearold blood-brain barrier. Trends in neurosciences. 2014;37(6):325–333.
11. Buguet A, Tapie P, Bert J. Reversal of the sleep/wake cycle disorder of sleeping
sickness after trypanosomicide treatment. Journal of sleep research. 1999;8(3):225–235.
12. Steverding D. The development of drugs for treatment of sleeping sickness: a
historical review. Parasites & vectors. 2010;3(1):15.
	
  

95

	
  
13. Magez S, Caljon G, Tran T, Stijlemans B, Radwanska M. Current status of
vaccination against African trypanosomiasis. Parasitology. 2010;137(14):2017–2027.
14. La Greca F, Magez S. Vaccination against trypanosomiasis. Human vaccines.
2011;7(11):1225–1233.
15. Ross R, Thomson D. A Case of Sleeping Sickness Studied by Precise Enumerative
Methods: Regular Periodical Increase of the Parasites Disclosed. Proceedings of the
Royal Society B: Biological Sciences. 1910;82(557):411–415.
16. Ross R, Thomson D. A Case of Sleeping Sickness Studied by Precise Enumerative
Methods: Further Observations. Proceedings. Biological sciences / The Royal Society.
1911;83(563):187–205.
17. Cross GA. Identification, purification and properties of clone-specific glycoprotein
antigens constituting the surface coat of Trypanosoma brucei. Parasitology.
1975;71(3):393–417.
18. Vickerman K, Luckins AG. Localization of variable antigens in the surface coat of
Trypanosoma brucei using ferritin conjugated antibody. Nature. 1969;224(5224):1125–
1126.
19. Grünfelder CG, Engstler M, Weise F, Schwarz H, Stierhof Y-D, Boshart M, Overath
P. Accumulation of a GPI-anchored protein at the cell surface requires sorting at multiple
intracellular levels. Traffic. 2002;3(8):547–559.
20. Jackson DG, Owen MJ, Voorheis HP. A new method for the rapid purification of
both the membrane-bound and released forms of the variant surface glycoprotein from
Trypanosoma brucei. The Biochemical journal. 1985;230(1):195–202.
21. Ziegelbauer K, Overath P. Organization of two invariant surface glycoproteins in the
surface coat of Trypanosoma brucei. Infection and immunity. 1993;61(11):4540–4545.
22. Sullivan L, Wall SJ, Carrington M, Ferguson MAJ. Proteomic selection of
immunodiagnostic antigens for human African trypanosomiasis and generation of a
prototype lateral flow immunodiagnostic device. Tschudi C, editor. PLoS neglected
tropical diseases. 2013;7(2):e2087.
23. Freymann D, Down J, Carrington M, Roditi I, Turner M, Wiley D. 2.9 A resolution
structure of the N-terminal domain of a variant surface glycoprotein from Trypanosoma
brucei. Journal of molecular biology. 1990;216(1):141–160.
24. Blum ML, Down JA, Gurnett AM, Carrington M, Turner MJ, Wiley DC. A structural
motif in the variant surface glycoproteins of Trypanosoma brucei. Nature.
1993;362(6421):603–609.

	
  

96

	
  
25. Carrington M, Miller N, Blum M, Roditi I, Wiley D, Turner M. Variant specific
glycoprotein of Trypanosoma brucei consists of two domains each having an
independently conserved pattern of cysteine residues. Journal of molecular biology.
1991;221(3):823–835.
26. Cross GAM, Kim H-S, Wickstead B. Capturing the variant surface glycoprotein
repertoire (the VSGnome) of Trypanosoma brucei Lister 427. Molecular and biochemical
parasitology. 2014;195(1):59–73.
27. Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, Bartholomeu DC,
Lennard NJ, Caler E, Hamlin NE, Haas B, et al. The genome of the African trypanosome
Trypanosoma brucei. Science (New York, NY). 2005;309(5733):416–422.
28. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GCM, Vervaet G,
Skepner E, Lewis NS, Spronken MIJ, Russell CA, et al. Substitutions near the receptor
binding site determine major antigenic change during influenza virus evolution. Science
(New York, NY). 2013;342(6161):976–979.
29. Palmer GH, Bankhead T, Lukehart SA. “Nothing is permanent but change-” antigenic
variation in persistent bacterial pathogens. Cellular microbiology. 2009;11(12):1697–
1705.
30. Nash T. Surface antigen variability and variation in Giardia lamblia. Parasitology
today (Personal ed.). 1992;8(7):229–234.
31. Kirkman LA, Deitsch KW. Recombination and Diversification of the Variant Antigen
Encoding Genes in the Malaria Parasite Plasmodium falciparum. Microbiology spectrum.
2014;2(6):437–449.
32. Hertz-Fowler C, Figueiredo LM, Quail MA, Becker M, Jackson A, Bason N, Brooks
K, Churcher C, Fahkro S, Goodhead I, et al. Telomeric expression sites are highly
conserved in Trypanosoma brucei. PloS one. 2008;3(10):e3527.
33. Alexandre S, Paindavoine P, Tebabi P, Pays A, Halleux S, Steinert M, Pays E.
Differential expression of a family of putative adenylate/guanylate cyclase genes in
Trypanosoma brucei. Molecular and biochemical parasitology. 1990;43(2):279–288.
34. Morgan RW, El-Sayed NM, Kepa JK, Pedram M, Donelson JE. Differential
expression of the expression site-associated gene I family in African trypanosomes. The
Journal of biological chemistry. 1996;271(16):9771–9777.
35. Liu AY, Van der Ploeg LH, Rijsewijk FA, Borst P. The transposition unit of variant
surface glycoprotein gene 118 of Trypanosoma brucei. Presence of repeated elements at
its border and absence of promoter-associated sequences. Journal of molecular biology.
1983;167(1):57–75.

	
  

97

	
  
36. Aline R, MacDonald G, Brown E, Allison J, Myler P, Rothwell V, Stuart K. (TAA)n
within sequences flanking several intrachromosomal variant surface glycoprotein genes
in Trypanosoma brucei. Nucleic acids research. 1985;13(9):3161–3177.
37. Campbell DA, van Bree MP, Boothroyd JC. The 5'-limit of transposition and
upstream barren region of a trypanosome VSG gene: tandem 76 base-pair repeats
flanking (TAA)90. Nucleic acids research. 1984;12(6):2759–2774.
38. McCulloch R, Rudenko G, Borst P. Gene conversions mediating antigenic variation
in Trypanosoma brucei can occur in variant surface glycoprotein expression sites lacking
70-base-pair repeat sequences. Molecular and cellular biology. 1997;17(2):833–843.
39. Pham VP, Qi CC, Gottesdiener KM. A detailed mutational analysis of the VSG gene
expression site promoter. Molecular and biochemical parasitology. 1996;75(2):241–254.
40. Günzl A, Bruderer T, Laufer G, Schimanski B, Tu L-C, Chung H-M, Lee P-T, Lee
MG-S. RNA polymerase I transcribes procyclin genes and variant surface glycoprotein
gene expression sites in Trypanosoma brucei. Eukaryotic Cell. 2003;2(3):542–551.
41. Parsons M, Nelson RG, Watkins KP, Agabian N. Trypanosome mRNAs share a
common 5' spliced leader sequence. Cell. 1984;38(1):309–316.
42. Berberof M, Vanhamme L, Tebabi P, Pays A, Jefferies D, Welburn S, Pays E. The 3'terminal region of the mRNAs for VSG and procyclin can confer stage specificity to gene
expression in Trypanosoma brucei. The EMBO Journal. 1995;14(12):2925–2934.
43. Lenardo MJ, Rice-Ficht AC, Kelly G, Esser KM, Donelson JE. Characterization of
the genes specifying two metacyclic variable antigen types in Trypanosoma brucei
rhodesiense. Proceedings of the National Academy of Sciences. 1984;81(21):6642–6646.
44. Barnes DA, Mottram JC, Agabian N. Bloodstream and metacyclic variant surface
glycoprotein gene expression sites of Trypanosoma brucei gambiense. Molecular and
biochemical parasitology. 1990;41(1):101–114.
45. Nagoshi YL, Alarcon CM, Donelson JE. The putative promoter for a metacyclic VSG
gene in African trypanosomes. Molecular and biochemical parasitology. 1995;72(12):33–45.
46. Ginger ML, Blundell PA, Lewis AM, Browitt A, Günzl A, Barry JD. Ex vivo and in
vitro identification of a consensus promoter for VSG genes expressed by metacyclicstage trypanosomes in the tsetse fly. Eukaryotic Cell. 2002;1(6):1000–1009.
47. Liu AY, Michels PA, Bernards A, Borst P. Trypanosome variant surface glycoprotein
genes expressed early in infection. Journal of molecular biology. 1985;182(3):383–396.
48. Rudenko G, McCulloch R, Dirks-Mulder A, Borst P. Telomere exchange can be an
important mechanism of variant surface glycoprotein gene switching in Trypanosoma
brucei. Molecular and biochemical parasitology. 1996;80(1):65–75.
	
  

98

	
  
49. Boothroyd CE, Dreesen O, Leonova T, Ly KI, Figueiredo LM, Cross GAM,
Papavasiliou FN. A yeast-endonuclease-generated DNA break induces antigenic
switching in Trypanosoma brucei. Nature. 2009;459(7244):278–281.
50. Glover L, Alsford S, Horn D. DNA break site at fragile subtelomeres determines
probability and mechanism of antigenic variation in African trypanosomes. PLoS
pathogens. 2013;9(3):e1003260.
51. McCulloch R, Barry JD. A role for RAD51 and homologous recombination in
Trypanosoma brucei antigenic variation. Genes & development. 1999;13(21):2875–2888.
52. Hartley CL, McCulloch R. Trypanosoma brucei BRCA2 acts in antigenic variation
and has undergone a recent expansion in BRC repeat number that is important during
homologous recombination. 2008;68(5):1237–1251.
53. Dreesen O, Li B, Cross GAM. Telomere structure and function in trypanosomes: a
proposal. Nature reviews Microbiology. 2007;5(1):70–75.
54. Hovel-Miner GA, Boothroyd CE, Mugnier MR, Dreesen O, Cross GAM,
Papavasiliou FN. Telomere length affects the frequency and mechanism of antigenic
variation in Trypanosoma brucei. PLoS pathogens. 2012;8(8):e1002900.
55. Van der Ploeg LH, Valerio D, De Lange T, Bernards A, Borst P, Grosveld FG. An
analysis of cosmid clones of nuclear DNA from Trypanosoma brucei shows that the
genes for variant surface glycoproteins are clustered in the genome. Nucleic acids
research. 1982;10(19):5905–5923.
56. Wickstead B, Ersfeld K, Gull K. The small chromosomes of Trypanosoma brucei
involved in antigenic variation are constructed around repetitive palindromes. Genome
research. 2004;14(6):1014–1024.
57. Marcello L, Barry JD. Analysis of the VSG gene silent archive in Trypanosoma
brucei reveals that mosaic gene expression is prominent in antigenic variation and is
favored by archive substructure. Genome research. 2007;17(9):1344–1352.
58. Bernards A, Van der Ploeg LH, Frasch AC, Borst P, Boothroyd JC, Coleman S, Cross
GA. Activation of trypanosome surface glycoprotein genes involves a duplicationtransposition leading to an altered 3' end. Cell. 1981;27(3 Pt 2):497–505.
59. Michels PA, Liu AY, Bernards A, Sloof P, Van der Bijl MM, Schinkel AH, Menke
HH, Borst P, Veeneman GH, Tromp MC, et al. Activation of the genes for variant surface
glycoproteins 117 and 118 in Trypanosoma brucei. Journal of molecular biology.
1983;166(4):537–556.
60. Pays E, Houard S, Pays A, Van Assel S, Dupont F, Aerts D, Huet-Duvillier G, Gomés
V, Richet C, Degand P. Trypanosoma brucei: the extent of conversion in antigen genes
may be related to the DNA coding specificity. Cell. 1985;42(3):821–829.

	
  

99

	
  
61. Kamper SM, Barbet AF. Surface epitope variation via mosaic gene formation is
potential key to long-term survival of Trypanosoma brucei. Molecular and biochemical
parasitology. 1992;53(1-2):33–44.
62. Barbet AF, Myler PJ, Williams RO, McGuire TC. Shared surface epitopes among
trypanosomes of the same serodeme expressing different variable surface glycoprotein
genes. Molecular and biochemical parasitology. 1989;32(2-3):191–199.
63. Aline RF, Myler PJ, Gobright E, Stuart KD. Early expression of a Trypanosoma
brucei VSG gene duplicated from an incomplete basic copy. The Journal of eukaryotic
microbiology. 1994;41(1):71–78.
64. Hall JPJ, Wang H, Barry JD. Mosaic VSGs and the scale of Trypanosoma brucei
antigenic variation. PLoS pathogens. 2013;9(7):e1003502.
65. Checchi F, Filipe JAN, Haydon DT, Chandramohan D, Chappuis F. Estimates of the
duration of the early and late stage of gambiense sleeping sickness. BMC infectious
diseases. 2008;8(1):16.
66. Coutte L, Botkin DJ, Gao L, Norris SJ. Detailed analysis of sequence changes
occurring during vlsE antigenic variation in the mouse model of Borrelia burgdorferi
infection. Coburn J, editor. PLoS pathogens. 2009;5(2):e1000293.
67. Zhuang Y, Futse JE, Brown WC, Brayton KA, Palmer GH. Maintenance of antibody
to pathogen epitopes generated by segmental gene conversion is highly dynamic during
long-term persistent infection. Infection and immunity. 2007;75(11):5185–5190.
68. Claessens A, Hamilton WL, Kekre M, Otto TD, Faizullabhoy A, Rayner JC,
Kwiatkowski D. Generation of antigenic diversity in Plasmodium falciparum by
structured rearrangement of Var genes during mitosis. Deitsch K, editor. PLoS genetics.
2014;10(12):e1004812.
69. Lu Y, Alarcon CM, Hall T, Reddy LV, Donelson JE. A strand bias occurs in point
mutations associated with variant surface glycoprotein gene conversion in Trypanosoma
rhodesiense. Molecular and cellular biology. 1994;14(6):3971–3980.
70. Lu Y, Hall T, Gay LS, Donelson JE. Point mutations are associated with a gene
duplication leading to the bloodstream reexpression of a trypanosome metacyclic VSG.
Cell. 1993;72(3):397–406.
71. Graham VS, Barry JD. Is point mutagenesis a mechanism for antigenic variation in
Trypanosoma brucei? Molecular and biochemical parasitology. 1996;79(1):35–45.
72. Glover L, McCulloch R, Horn D. Sequence homology and microhomology dominate
chromosomal double-strand break repair in African trypanosomes. Nucleic acids
research. 2008;36(8):2608–2618.

	
  

100

	
  
73. Glover L, Jun J, Horn D. Microhomology-mediated deletion and gene conversion in
African trypanosomes. Nucleic acids research. 2011;39(4):1372–1380.
74. Barbet AF, Davis WC, McGuire TC. Cross-neutralization of two different
trypanosome populations derived from a single organism. Nature. 1982;300(5891):453–
456.
75. Roth CW, Longacre S, Raibaud A, Baltz T, Eisen H. The use of incomplete genes for
the construction of a Trypanosoma equiperdum variant surface glycoprotein gene. The
EMBO Journal. 1986;5(5):1065–1070.
76. Roth C, Bringaud F, Layden RE, Baltz T, Eisen H. Active late-appearing variable
surface antigen genes in Trypanosoma equiperdum are constructed entirely from
pseudogenes. Proceedings of the National Academy of Sciences of the United States of
America. 1989;86(23):9375–9379.
77. Gray AR. Antigenic variation in a strain of Trypanosoma brucei transmitted by
Glossina morsitans and G. palpalis. Journal of general microbiology. 1965;41(2):195–
214.
78. Myler PJ, Allen AL, Agabian N, Stuart K. Antigenic variation in clones of
Trypanosoma brucei grown in immune-deficient mice. Infection and immunity.
1985;47(3):684–690.
79. Miller EN, Turner MJ. Analysis of antigenic types appearing in first relapse
populations of clones of Trypanosoma brucei. Parasitology. 1981;82(1):63–80.
80. Morrison LJ, Majiwa P, Read AF, Barry JD. Probabilistic order in antigenic variation
of Trypanosoma brucei. International journal for parasitology. 2005;35(9):961–972.
81. Lythgoe KA, Morrison LJ, Read AF, Barry JD. Parasite-intrinsic factors can explain
ordered progression of trypanosome antigenic variation. Proceedings of the National
Academy of Sciences of the United States of America. 2007;104(19):8095–8100.
82. Kosinski RJ. Antigenic variation in trypanosomes: a computer analysis of variant
order. Parasitology. 1980;80(2):343–357.
83. Gjini E, Haydon DT, Barry JD, Cobbold CA. Critical Interplay between Parasite
Differentiation, Host Immunity, and Antigenic Variation in Trypanosome Infections. The
American naturalist. 2010 Aug 17.
84. Gjini E, Haydon DT, Barry JD, Cobbold CA. Linking the antigen archive structure to
pathogen fitness in African trypanosomes. Proceedings. Biological sciences / The Royal
Society. 2013;280(1753):20122129–20122129.
85. Antia R, Nowak MA, Anderson RM. Antigenic variation and the within-host
dynamics of parasites. Proceedings of the National Academy of Sciences of the United
States of America. 1996;93(3):985–989.
	
  

101

	
  
86. Recker M, Nee S, Bull PC, Kinyanjui S, Marsh K, Newbold C, Gupta S. Transient
cross-reactive immune responses can orchestrate antigenic variation in malaria. Nature.
2004;429(6991):555–558.
87. Turner CM. The rate of antigenic variation in fly-transmitted and syringe-passaged
infections of Trypanosoma brucei. FEMS microbiology letters. 1997;153(1):227–231.
88. Turner CM, Barry JD. High frequency of antigenic variation in Trypanosoma brucei
rhodesiense infections. Parasitology. 1989;99 Pt 1:67–75.
89. Lamont GS, Tucker RS, Cross GA. Analysis of antigen switching rates in
Trypanosoma brucei. Parasitology. 1986;92 ( Pt 2):355–367.
90. Doyle JJ, Hirumi H, Hirumi K, Lupton EN, Cross GA. Antigenic variation in clones
of animal-infective Trypanosoma brucei derived and maintained in vitro. Parasitology.
1980;80(2):359–369.
91. Aitcheson N, Talbot S, Shapiro J, Hughes K, Adkin C, Butt T, Sheader K, Rudenko
G. VSG switching in Trypanosoma brucei: antigenic variation analysed using RNAi in
the absence of immune selection. Molecular microbiology. 2005;57(6):1608–1622.
92. Eyford BA, Ahmad R, Enyaru JC, Carr SA, Pearson TW. Identification of
Trypanosome proteins in plasma from African sleeping sickness patients infected with T.
b. rhodesiense. Sturtevant J, editor. PloS one. 2013;8(8):e71463.
93. Seed JR, Edwards R, Sechelski J. The ecology of antigenic variation. The Journal of
protozoology. 1984;31(1):48–53.
94. Diffley P. Trypanosomal surface coat variant antigen causes polyclonal lymphocyte
activation. Journal of immunology (Baltimore, Md : 1950). 1983;131(4):1983–1986.
95. Musoke AJ, Nantulya VM, Barbet AF, Kironde F, McGuire TC. Bovine immune
response to African ;trypanosomes: specific antibodies to variable surface glycoproteins
of Trypanosoma brucei. Parasite immunology. 1981;3(2):97–106.
96. Dempsey WL, Mansfield JM. Lymphocyte function in experimental African
trypanosomiasis. V. Role of antibody and the mononuclear phagocyte system in variantspecific immunity. Journal of immunology (Baltimore, Md : 1950). 1983;130(1):405–
411.
97. Radwanska M, Guirnalda P, De Trez C, Ryffel B, Black S, Magez S.
Trypanosomiasis-induced B cell apoptosis results in loss of protective anti-parasite
antibody responses and abolishment of vaccine-induced memory responses. PLoS
pathogens. 2008;4(5):e1000078.
98. Corsini AC, Clayton C, Askonas BA, Ogilvie BM. Suppressor cells and loss of B-cell
potential in mice infected with Trypanosoma brucei. Clinical and experimental
immunology. 1977;29(1):122–131.
	
  

102

	
  
99. Bockstal V, Guirnalda P, Caljon G, Goenka R, Telfer JC, Frenkel D, Radwanska M,
Magez S, Black SJ. T. brucei infection reduces B lymphopoiesis in bone marrow and
truncates compensatory splenic lymphopoiesis through transitional B-cell apoptosis.
Wynn TA; Wynn TA, editors. PLoS pathogens. 2011;7(6):e1002089.
100. Magez S, Schwegmann A, Atkinson R, Claes F, Drennan M, DE Baetselier P,
Brombacher F. The role of B-cells and IgM antibodies in parasitemia, anemia, and VSG
switching in Trypanosoma brucei-infected mice. PLoS pathogens. 2008;4(8):e1000122.
101. Lutz C, Ledermann B, Kosco-Vilbois MH, Ochsenbein AF, Zinkernagel RM,
Köhler G, Brombacher F. IgD can largely substitute for loss of IgM function in B cells.
Nature. 1998;393(6687):797–801.
102. Chen K, Cerutti A. New insights into the enigma of immunoglobulin D.
Immunological reviews. 2010;237(1):160–179.
103. Radwanska M, Magez S, Michel A, Stijlemans B, Geuskens M, Pays E.
Comparative analysis of antibody responses against HSP60, invariant surface
glycoprotein 70, and variant surface glycoprotein reveals a complex antigen-specific
pattern of immunoglobulin isotype switching during infection by Trypanosoma brucei.
Infection and immunity. 2000;68(2):848–860.
104. Vickerman K. On the surface coat and flagellar adhesion in trypanosomes. Journal
of cell science. 1969;5(1):163–193.
105. Schwede A, Macleod OJS, Macgregor P, Carrington M. How Does the VSG Coat of
Bloodstream Form African Trypanosomes Interact with External Proteins? Gubbels M-J,
editor. PLoS pathogens. 2015;11(12):e1005259.
106. Schwede A, Jones N, Engstler M, Carrington M. The VSG C-terminal domain is
inaccessible to antibodies on live trypanosomes. Molecular and biochemical parasitology.
2011;175(2):201–204.
107. Hsia R, Beals T, Boothroyd JC. Use of chimeric recombinant polypeptides to
analyse conformational, surface epitopes on trypanosome variant surface glycoproteins.
Molecular microbiology. 1996;19(1):53–63.
108. Engstler M, Pfohl T, Herminghaus S, Boshart M, Wiegertjes G, Heddergott N,
Overath P. Hydrodynamic flow-mediated protein sorting on the cell surface of
trypanosomes. Cell. 2007;131(3):505–515.
109. Overath P, Stierhof YD, Wiese M. Endocytosis and secretion in trypanosomatid
parasites - Tumultuous traffic in a pocket. Trends in cell biology. 1997;7(1):27–33.
110. Engstler M, Thilo L, Weise F, Grünfelder CG, Schwarz H, Boshart M, Overath P.
Kinetics of endocytosis and recycling of the GPI-anchored variant surface glycoprotein in
Trypanosoma brucei. Journal of cell science. 2004;117(Pt 7):1105–1115.

	
  

103

	
  
111. Baltz T, Giroud C, Bringaud F, Eisen H, Jacquemot C, Roth CW. Exposed epitopes
on a Trypanosoma equiperdum variant surface glycoprotein altered by point mutations.
The EMBO Journal. 1991;10(7):1653–1659.
112. Schleifer KW, Filutowicz H, Schopf LR, Mansfield JM. Characterization of T
helper cell responses to the trypanosome variant surface glycoprotein. Journal of
immunology (Baltimore, Md : 1950). 1993;150(7):2910–2919.
113. Hertz CJ, Filutowicz H, Mansfield JM. Resistance to the African trypanosomes is
IFN-gamma dependent. Journal of immunology (Baltimore, Md : 1950).
1998;161(12):6775–6783.
114. Dagenais TR, Demick KP, Bangs JD, Forest KT, Paulnock DM, Mansfield JM. Tcell responses to the trypanosome variant surface glycoprotein are not limited to
hypervariable subregions. Infection and immunity. 2009;77(1):141–151.
115. Camara M, Camara O, Ilboudo H, Sakande H, Kaboré J, N'Dri L, Jamonneau V,
Bucheton B. Sleeping sickness diagnosis: use of buffy coats improves the sensitivity of
the mini anion exchange centrifugation test. Tropical medicine & international health :
TM & IH. 2010;15(7):796–799.
116. Grabherr MG, Haas BJ, Yassour M, Levin JZ, Thompson DA, Amit I, Adiconis X,
Fan L, Raychowdhury R, Zeng Q, et al. Full-length transcriptome assembly from RNASeq data without a reference genome. Nature biotechnology. 2011;29(7):644–652.
117. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G,
Mesirov JP. Integrative genomics viewer. Nature biotechnology. 2011;29(1):24–26.
118. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV):
high-performance genomics data visualization and exploration. Briefings in
bioinformatics. 2013;14(2):178–192.
119. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg
SL, Wold BJ, Pachter L. Transcript assembly and quantification by RNA-Seq reveals
unannotated transcripts and isoform switching during cell differentiation. Nature
biotechnology. 2010;28(5):511–515.
120. Storvall H, Ramsköld D, Sandberg R. Efficient and comprehensive representation of
uniqueness for next-generation sequencing by minimum unique length analyses. PloS
one. 2013;8(1):e53822.
121. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D,
Falloon J, Davey RT, Dewar RL, et al. Multiple, linked human immunodeficiency virus
type 1 drug resistance mutations in treatment-experienced patients are missed by standard
genotype analysis. Journal of clinical microbiology. 2005;43(1):406–413.

	
  

104

	
  
122. Nakamura K, Oshima T, Morimoto T, Ikeda S, Yoshikawa H, Shiwa Y, Ishikawa S,
Linak MC, Hirai A, Takahashi H, et al. Sequence-specific error profile of Illumina
sequencers. Nucleic acids research. 2011;39(13):e90–e90.
123. Lanham SM, Godfrey DG. Isolation of salivarian trypanosomes from man and other
mammals using DEAE-cellulose. Experimental parasitology. 1970;28(3):521–534.
124. Vassella E, Reuner B, Yutzy B, Boshart M. Differentiation of African trypanosomes
is controlled by a density sensing mechanism which signals cell cycle arrest via the
cAMP pathway. Journal of cell science. 1997;110 ( Pt 21):2661–2671.
125. Lu J, Panavas T, Thys K, Aerssens J, Naso M, Fisher J, Rycyzyn M, Sweet RW. IgG
variable region and VH CDR3 diversity in unimmunized mice analyzed by massively
parallel sequencing. Molecular Immunology. 2014;57(2):274–283.
126. Navarro M, Cross GA. DNA rearrangements associated with multiple consecutive
directed antigenic switches in Trypanosoma brucei. Molecular and cellular biology.
1996;16(7):3615–3625.
127. Wirtz E, Leal S, Ochatt C, Cross GA. A tightly regulated inducible expression
system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma
brucei. Molecular and biochemical parasitology. 1999;99(1):89–101.
128. Claes F, Vodnala SK, van Reet N, Boucher N, Lunden-Miguel H, Baltz T,
Goddeeris BM, Büscher P, Rottenberg ME. Bioluminescent imaging of Trypanosoma
brucei shows preferential testis dissemination which may hamper drug efficacy in
sleeping sickness. PLoS neglected tropical diseases. 2009;3(7):e486.
129. Van Meirvenne N, Janssens PG, Magnus E. Antigenic variation in syringe passaged
populations of Trypanosoma (Trypanozoon) brucei. 1. Rationalization of the
experimental approach. Annales de la Société belge de médecine tropicale. 1975;55(1):1–
23.
130. Mugnier MR, Cross GAM, Papavasiliou FN. The in vivo dynamics of antigenic
variation in Trypanosoma brucei. Science (New York, NY). 2015;347(6229):1470–1473.
131. Seed JR. Competition among serologically different clones of Trypanosoma brucei
gambiense in vivo. The Journal of protozoology. 1978;25(4):526–529.
132. Marcello L, Barry JD. From silent genes to noisy populations-dialogue between the
genotype and phenotypes of antigenic variation. The Journal of eukaryotic microbiology.
2007;54(1):14–17.
133. Thon G, Baltz T, Giroud C, Eisen H. Trypanosome variable surface glycoproteins:
composite genes and order of expression. Genes & development. 1990;4(8):1374–1383.

	
  

105

	
  
134. González-Andrade P, Camara M, Ilboudo H, Bucheton B, Jamonneau V,
Deborggraeve S. Diagnosis of trypanosomatid infections: targeting the spliced leader
RNA. The Journal of molecular diagnostics : JMD. 2014;16(4):400–404.
135. Chappuis F, Loutan L, Simarro P, Lejon V, Büscher P. Options for field diagnosis of
human african trypanosomiasis. Clinical microbiology reviews. 2005;18(1):133–146.
136. Hutchinson OC, Picozzi K, Jones NG, Mott H, Sharma R, Welburn SC, Carrington
M. Variant Surface Glycoprotein gene repertoires in Trypanosoma brucei have diverged
to become strain-specific. BMC genomics. 2007;8(1):234.
137. Jackson AP, Berry A, Aslett M, Allison HC, Burton P, Vavrova-Anderson J, Brown
R, Browne H, Corton N, Hauser H, et al. Antigenic diversity is generated by distinct
evolutionary mechanisms in African trypanosome species. Proceedings of the National
Academy of Sciences of the United States of America. 2012;109(9):3416–3421.
138. Jennings FW, Whitelaw DD, Holmes PH, Chizyuka HG, Urquhart GM. The brain as
a source of relapsing Trypanosoma brucei infection in mice after chemotherapy.
International journal for parasitology. 1979;9(4):381–384.
139. Ehrlich P. Chemotherapeutische trypanosomen-studien. 1907.
140. Truc P, Lejon V, Magnus E, Jamonneau V, Nangouma A, Verloo D, Penchenier L,
Büscher P. Evaluation of the micro-CATT, CATT/Trypanosoma brucei gambiense, and
LATEX/T b gambiense methods for serodiagnosis and surveillance of human African
trypanosomiasis in West and Central Africa. Bulletin of the World Health Organization.
2002;80(11):882–886.
141. Sullivan L, Fleming J, Sastry L, Mehlert A, Wall SJ, Ferguson MAJ. Identification
of sVSG117 as an immunodiagnostic antigen and evaluation of a dual-antigen lateral
flow test for the diagnosis of human African trypanosomiasis. Raper J, editor. PLoS
neglected tropical diseases. 2014;8(7):e2976.
142. Dukes P, Gibson WC, Gashumba JK, Hudson KM, Bromidge TJ, Kaukus A,
Asonganyi T, Magnus E. Absence of the LiTat 1.3 (CATT antigen) gene in Trypanosoma
brucei gambiense stocks from Cameroon. Acta tropica. 1992;51(2):123–134.
143. Fairbairn H, Burtt E. The Infectivity to Man of a Strain of Trypanosoma rhodesiense
transmitted cyclically by Glossina morsitans through Sheep and Antelope : Evidence that
Man requires a Minimum Infective Dose of Meta-cyelic Trypanosomes. Ann trop Med
Parasit. 1946;40(3/4):270–313.
144. Turner CMR, Barry JD, Maudlin I, Vickerman K. An estimate of the size of the
metacyclic variable antigen repertoire of Trypanosoma brucei rhodesiense. Parasitology.
1988;97(02):269–276.

	
  

106

	
  
145. Lenardo MJ, Esser KM, Moon AM, Van der Ploeg LH, Donelson JE. Metacyclic
variant surface glycoprotein genes of Trypanosoma brucei subsp. rhodesiense are
activated in situ, and their expression is transcriptionally regulated. Molecular and
cellular biology. 1986;6(6):1991–1997.
146. McKeown SR. Defining normoxia, physoxia and hypoxia in tumours-implications
for treatment response. The British journal of radiology. 2014;87(1035):20130676.
147. Vassella E, Abbeele Den JV, Bütikofer P, Renggli CK, Furger A, Brun R, Roditi I.
A major surface glycoprotein of trypanosoma brucei is expressed transiently during
development and can be regulated post-transcriptionally by glycerol or hypoxia. Genes &
development. 2000;14(5):615–626.
148. Kraemer SM, Smith JD. A family affair: var genes, PfEMP1 binding, and malaria
disease. Current opinion in microbiology. 2006;9(4):374–380.
149. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing
reads. EMBnet journal. 2011;17:10–12.
150. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient
alignment of short DNA sequences to the human genome. Genome biology.
2009;10(3):R25.
151. Li W, Godzik A. Cd-hit: a fast program for clustering and comparing large sets of
protein or nucleotide sequences. Bioinformatics (Oxford, England). 2006;22(13):1658–
1659.
152. Fu L, Niu B, Zhu Z, Wu S, Li W. CD-HIT: accelerated for clustering the nextgeneration sequencing data. Bioinformatics (Oxford, England). 2012;28(23):3150–3152.
	
  

	
  

107

